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Abstract
Type 1 diabetes mellitus is a disease characterised by inadequate insulin secretion,
causing damaging imbalance to the glucoregulatory system. Cutting edge therapies
involve the use of an artificial pancreas, that is a device capable of maintaining a
physiological glucose concentration through accurate insulin infusions. Customisation
of these devices to the individual needs may be accomplished provided that a precise
identification of the patient is performed.
This work considers optimal model-based design of experiment techniques to devise
a new clinical test for the identification of model parameters in subjects affected by
T1DM. The pivotal feature required for this test is its implementation feasibility. In
order to satisfy this requirement, a novel approach based on heuristic indices is in-
troduced to assess several aspects that could impact on the practical applicability of
the designed protocol. Among the criteria considered, a particular emphasis is put
on assuring safety conditions for the test and on extracting the maximum information
content for a precise estimation of the model parameters.
A robust clinical protocol is devised, which exhibits statistically satisfactory parameter
estimation capabilities and complies with the requirements imposed by practicality.
iii

Riassunto
Il diabete mellito di tipo 1 e` una malattia autoimmune che causa la progressiva di-
struzione delle cellule beta del pancreas, da cui deriva l’incapacita` di produrre insulina
e quindi di regolare la glicemia. Pur riguardando una percentuale ridotta della popo-
lazione diabetica, colpisce milioni di persone in tutto il mondo, generando una spesa
economica di miliardi di dollari per la sua cura e il trattamento delle complicazioni che
ne derivano.
Il trattamento tradizionale richiede la somministrazione giornaliera di molteplici dosi
di insulina da parte del paziente. Questo metodo, oltre ad essere invasivo, non consente
un controllo ottimale della glicemia ed e` influenzato dall’abilita` del paziente. La terapia
piu` promettente in fase di sviluppo consiste nell’impiego di un pancreas artificiale, che
consenta di sopperire all’incapacita` del paziente di produrre insulina da se`. Il funziona-
mento di questo dispositivo sfrutta un algoritmo di controllo basato su un modello del
paziente diabetico. Affinche` questa terapia risponda alle esigenze del singolo soggetto,
e` richiesta un’accurata identificazione dei parametri del modello mediante opportuni
test clinici.
Questa tesi si propone di progettare test clinici che consentano un’identificazione otti-
male dei parametri di modelli fisiologici relativi a soggetti diabetici, tali da soddisfare
i requisiti di sicurezza richiesti per una loro implementazione clinica.
Il metodo impiegato nell’analisi e` la progettazione di esperimenti basata su modello,
che permette di ottenere la procedura ottimale da seguire nell’esecuzione del test sia
in termini di campionamento sia di variabili di controllo. La progettazione del nuovo
protocollo e` volta a massimizzare la quantitita` di informazione ottenibile attraverso un
campionamento discreto, ottemperando ad alcuni vincoli imposti sulla sicurezza.
La capacita` identificativa dei test viene valutata tramite alcune statistiche, relative
alla stima dei parametri su due pazienti simulati, affetti da diabete in maniera piu` o
meno severa. La valutazione complessiva dell’attuabilita` del test avviene sulla base
di una serie di indici euristici introdotti a tal proposito. Questi, oltre a considerare
l’informazione fornita dal test, tengono in considerazione la sua sicurezza, invasivita` e
durata.
L’analisi prende avvio dalla valutazione dei due test tradizionali usati in ambito clinico:
v
il test di tolleranza orale al glucosio e quello endovenoso. Partendo da tali basi, il lavoro
si estende poi alla progettazione di nuovi protocolli con l’obiettivo principale di garan-
tire una identificazione statisticamente soddisfacente del soggetto. I risultati forniscono
importanti indicazioni, tra cui la migliore efficacia di un test orale per l’identificazione
ma, al tempo stesso, la necessita` di migliorare la sicurezza associata a tali protocolli.
Al fine di garantire una maggiore affidabilita` al test, a fronte dell’elevata variabilita`
osservata nelle riposte da soggetti differenti, si ricorre all’impiego di tecniche di pro-
gettazione robusta. Questo metodo simula una popolazione diabetica per trarre in-
formazioni statistiche sulla variabilita` media osservata nelle risposte, sulla base della
quale viene progettato un nuovo protocollo. Il test ottenuto in tal modo, oltre a rea-
lizzare stime parametriche soddisfacenti, si dimostra efficace nell’ottemperare a tutti i
requisiti richiesti per un’implementazione clinica, in modo particolare garantendo un
sostanziale miglioramento del livello di sicurezza per il paziente.
vi
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Introduction
Type 1 diabetes mellitus (T1DM) is a disease affecting millions of people around the
world and causing billions of dollars to be spent on its treatment and complications
every year. This metabolic disorder is characterised by the lack of insulin in the or-
ganism, due to the autoimmune destruction of the pancreatic beta cells. As a result,
high blood glucose concentrations are observed in the patient, which lead to unsafe
conditions that, if prolonged over time, may cause severe damage.
The typical management of this disease requires the patient to perform multiple daily
insulin injections, in order to maintain the normoglycaemia. There are several draw-
backs related to this therapy, such as it is highly invasive and relies on the ability of
the patient to keep his/her glycaemia under control.
The most promising therapy for the future is represented by the use of an artificial
pancreas, that is a device capable of mimicking the action of the pancreas in insulin
delivery. Such a device requires a control algorithm for the calculation of the insulin
dosage based on the continuous glycaemia measurements. The availability of a phys-
iological model, describing the glucoregulatory system of a diabetic patient, allows
assessing the algorithm performance on a simulated subject. Alternatively, in model
predictive control, the model itself is used in the algorithm, so as to customise the
therapy to the individual.
A tailored therapy requires a precise identification of the model parameters of the
patient by means of experimental measurements. Since the condition of the subject
is usually unknown a priori, it is necessary to adopt optimal design of experiments
techniques in order to devise tests, which comply with safety requirements. The goal
of the thesis is to apply a model-based design of experiments approach to conceive
clinical tests allowing for a statistically satisfactory identification of the parameters of
a simple physiological model. Since the main focus is on the feasibility of the designed
protocol, a novel approach based on five heuristic indices is introduced based on which
the overall performance of the different designs may be compared.
The first chapter presents an overview of the disease and its global impact. Then, the
chief clinical tests used for clinical and research purposes are discussed, along with the
current therapy and the future perspectives on its management. Much relevance is
2 Introduction
given to the review of the most important physiological models of T1DM that have
been proposed over the years for the description of the glucose and insulin dynamics.
Finally, the motivation for the use of a model-based design of experiments (MBDoE)
procedure is explained, and the objectives of the thesis are outlined.
The second chapter deals with the mathematical part of the model-based design of
experiments. Firstly, the Lynch and Bequette model is detailed, since it is the one
selected for the simulation of the diabetic patients in this work. Secondly, the theory
underlying MBDoE is presented, along with the in silico generation of experimental
data and the parameter estimation procedure. Lastly, five heuristic indices are intro-
duced, so as to evaluate the feasibility of the designed protocols.
Chapter three is about the preliminary analysis of the Lynch and Bequette model,
by means of two different standard clinical tests. This allows to understand how the
model, i.e. the simulated patient, reacts to different types of stimuli and how much
information can be extracted with these two protocols.
In chapter four, the different designed protocols obtained with MBDoE are presented
and their parameter estimation capability evaluated using two parametric sets, repre-
senting diabetic patients with different illness severity. Eventually, a comparison among
the several designed tests is made in order to evaluate their overall performance.
In chapter five, a robust design of experiments approach is adopted to reduce the vari-
ability of the outputs. This method allows to devise a clinical protocol which improves
the safety conditions when an unknown subject is to be identified.
Chapter 1
Diabetes mellitus
In this chapter an overview of diabetes mellitus is presented with a focus on the dis-
ease, its diagnosis and therapy. The different types of diabetes are analysed, with a
particular emphasis on type 1, which is the main objective of this work. Then, the
social and economic impact of diabetes are discussed and the main glucose tolerance
tests utilised for its diagnosis are outlined. Much relevance is given to an overview of
the proposed physiological models of type 1 diabetes and their role in state-of-the-art
therapies, such as the use of an artificial pancreas. Going into detail, the importance
of designing suitable clinical protocols for the identification of the parameters of phys-
iological models is dealt with. Finally, the objectives of this thesis are pointed out
along with a novel approach based on indices for the evaluation of the designed clinical
protocols.
1.1 Introduction
Carbohydrates introduced in the body through food are processed in the digestion into
their monomers: glucose, galactose and fructose. Both galactose and fructose are con-
verted into glucose by the liver, in order to make them usable for the cells. Glucose
constitutes the main source of energy for the organism and is carried to the various
parts of the body where is needed through blood circulation. The level of glucose in
blood is referred to as glycaemia and it is regulated by the glucoregulatory system
through two hormones secreted by pancreas: insulin and glucagon.
Insulin is synthesised by beta cells, which are located in the islets of Langerhans in the
pancreas. This hormone is responsible for some of the glucose to be directly used by
some cells, such as cerebral cells and red blood cells, and for the excess to be stored
as glycogen in the liver. On the opposite, glucagon is secreted by alpha cells in the
pancreas and carries out the conversion of glycogen back to glucose when glycaemia
decreases.
4 Diabetes mellitus
Diabetes mellitus is a metabolic disorder characterised by high glucose concentrations
in blood due to insufficient insulin secretion, insulin effectiveness or both. Enduring de-
viations of blood glucose concentration from the physiological values (normoglycaemia)
are denoted as hyperglycaemia, if they exceed the upper level of normoglycaemia, and
hypoglycaemia, if they go beyond its lower limit. Persistent hyperglycaemic conditions
can cause serious consequences mainly to the nerves and blood vessels. If the subject
does not receive an adequate treatment, potentially deadly conditions may occur, such
as cardiovascular diseases, amputation, blindness and kidney failure. Similarly, hypo-
glycemic conditions should be avoided since they can lead to shakiness, fatigue and
eventually coma.
1.2 Diabetes classification
Three types of diabetes mellitus have been identified: type 1 and type 2, which regard
almost the totality of the people affected, and gestational diabetes, which accounts for
the remaining part.
1.2.1 Type 1 diabetes mellitus
Type 1 diabetes mellitus (T1DM), previously referred to as juvenile-onset or insulin
dependent diabetes mellitus, is caused by the autoimmune destruction of pancreatic
islet beta cells. Being incapable of producing the insulin by itself, the subject needs
multiple daily external administrations for survival.
In the absence of insulin, the three main target tissues where glucose is normally
delivered (liver, muscle and fat) are not capable of taking it up so that it flows, along
with amino acids and fatty acids, in the bloodstream. Inability of glucose to enter
into the cells causes the organism to use fatty acids for energy production; however,
fatty acids utilisation produces ketones, which tend to accumulate in blood being non-
volatile and, due to their acidity, lower pH.
Symptoms are increased urination and thirst, constant hunger, weight loss, recurrent
blurred vision and fatigue.
T1DM typically aﬄicts children and young adults and no evidence of a correlation
with body weight has been identified. The causes of this disease are still unknown,
even though it is generally agreed that T1DM is related to a complex interaction
between genes and environmental factors. In light of that, it is not preventable with
the current knowledge. Nevertheless, a swift diagnosis and an adequate therapy allow
the individual to conduct a decent life, even if life expectancy is reduced by more than
10 years [1].
T1DM is the target of this work because no prevention is possible and, although it
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affects only 10% of the diabetic patients, it still represents a huge number of people.
1.2.2 Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM), previously known as adult-onset or non-insulin
dependent diabetes mellitus, derives from a relative insulin deficiency. Subjects affected
by this illness show heterogeneous conditions ranging from a severe resistance to insulin
but unaltered secretion capability to defects in insulin secretion [2]. The symptoms of
T2DM may be similar to those of T1DM (excessive urination and thirst, increased
hunger, vision changes), even though they are less evident, so that the diagnosis often
occurs some years after the disease onset.
T2DM accounts for nearly 90% of the people affected by diabetes all over the world
[3] and strong correlations have been highlighted between its onset and excess body
weight and sedentary lifestyle.
1.2.3 Gestational diabetes mellitus
Gestational diabetes mellitus (GDM) is characterised by hyperglycaemic levels during
pregnancy in an individual not previously affected by diabetes. Occurrence of this
disease may lead to complications during pregnancy and delivery, moreover, it enhances
the risk of incurring in type 2 diabetes mellitus in future life.
1.3 Global impact of diabetes mellitus
According to the World Health Organization [4], in 2012 diabetes was directly respon-
sible for the death of 1.5 million people in the world, especially in low-income countries,
and this number is expected to increase more than 50% in the next 10 years. In 2014,
diabetes was estimated to affect 422 million adults around the world [5]. From Figure
1.1, it can be observed as the number of people affected in the period 1980-2014 has
significantly increased in poor and developing countries (in orange and green). On the
contrary, in western countries (in light blue), apart from the USA, prevention started
earlier, hence the increase has slowed down.
These astounding figures explain why, in developed countries, 10% or more of the
health budget is allocated to the treatment of diabetes and its complications. Direct
medical costs associated with diabetes are related to its prevention and treatment.
These include inpatient hospital care, outpatient and emergency care, medications and
medical supplies such as injection devices and self-monitoring equipment.
Based on recent cost estimates, it has been evaluated the direct annual cost of diabetes
to the world amounts to US$ 825 billion [7]. This figure has been estimated by the
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Figure 1.1. Countries with the largest number of adults with diabetes in 1980 and 2014 (colours for
each country indicates its region) [6].
International Diabetes Federation to have more than tripled over the period 2003-2013
due to the increase in the number of people affected and rise in the per capita diabetes
spending. The national expense for diabetes ranks these countries at the forefront:
China ($ 127 billion), the USA ($ 105 billion), India ($ 73 billion) and Japan ($ 37
billion).
Nearly 60% of the global cost is borne by low-income and middle-income countries,
where significant parts of medical expenses are generally paid out-of-the-pocket [7],
which affects treatment adherence and causes serious financial hardships for patients
and their families.
1.4 Standard clinical tests
Several standard clinical tests have been set up for the diagnosis of diabetes and some
of them are also used for research purposes. They are generally based on a stimulus-
response pattern, so the patient receives a glucose meal and glycaemia is measured
at fixed times. The diagnosis is straightforward once the test results are available by
comparison with standard validated values. A quick overview of the most established
clinical tests is presented below.
• The Oral Glucose Tolerance Test (OGTT) is widely used for screening, since it
is the one recommended by the World Health Organization [8]. The test is to be
performed in the morning after the subject, in the 3 days before, has followed an
Standard clinical tests 7
unrestricted diet with at least 150 g carbohydrates/d and an overnight fast prior
to the test. A pre-test sample is collected to assess fasting values, then, at t=0
min, 75 g of glucose are administered in the form of a drink with 250-300 mL of
water over the course of 5 min. For screening purposes, samples are taken at end
of the test, which lasts 2 hours while, if the aim is model identification, more
samples are collected in between.
• The Intravenous Glucose Tolerance Test (IVGTT) was proposed by Bergman
[9] in 1981 to evaluate glucose and insulin sensitivity. The patient has to be
consumed at least 300 g carbohydrates/d in the 3 days preceding the test, which
is carried out in the morning following an overnight fast. Three 2-mL pre-test
samples are taken 13, 8 and 3 min prior to the beginning of the test to monitor
basal values, following which an intravenous glucose injection is performed at
300 mg/kg in an antecubital vein, starting at t=0 min and over a 60 s duration.
During the test, 23 2-mL additional samples are collected at times: 2, 4, 6, 8, 10,
12, 14, 16, 19, 22, 27, 32, 42, 52, 62, 72, 82, 92, 102, 122, 142, 162 and 182 min.
Since it is more invasive for the subject, it is mainly used for research purposes,
for instance to detect insulin sensitivity in response to a variation in glycaemia.
• The Postprandial Glucose Test is used both for screening and evaluating the
effectiveness of a treatment in diabetic patients. It is executed after the subject
has eaten a meal containing at least 100 g of carbohydrates and has fasted for 2
h with a variable sampling schedule.
• The Euglycemic Hyperinsulinemic Clamp, discussed by De Fronzo et al. [10], is
a test used to evaluate the insulin resistance while injecting an amount of glucose
sufficient to compensate the rise in insulin. The test lasts 2 h and the glucose
infusion profile applied in the last 30 minutes quantifies insulin sensitivity.
The OGTT is currently the most employed test for diabetes diagnosis because it has
been widely validated and, like the postprandial, is an oral test, which means it is
less invasive for the subject. Nevertheless, the choice of the optimal test for research
purposes is not trivial and it is worth being carefully analysed. In fact, it must take
into account many different aspects, such as:
• low stress for the subject,
• maximisation of the information obtainable,
• inherent safety throughout the execution.
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1.5 Type 1 diabetes mellitus management
Safety conditions for the patient affected by T1DM are ensured by maintaining its nor-
moglycaemic values through exogenous injections of insulin to prevent hyperglycaemic
conditions. Dosage and timing of the insulin administration are crucial to avoid also
the risk of incurring in hypoglycaemic values. In the past, the approach consisted of
instructing the subject to check the glycaemia during the day through self-monitoring
of blood glucose. Blood samples were collected from the fingertips and glycaemia was
read on a specific device. Multiple insulin injections are required during the day, usu-
ally long-lasting effect insulin is administered once a day and additionally short-acting
insulin before meals. This therapy is not expensive but it is invasive, due to the exoge-
nous injections, and does not allow an optimal glycemic control. Despite this technique
is still used, thanks to technological improvement more effective methods have emerged
allowing for continuous glucose monitoring. Frequent measurement permits, on the one
hand, to study the dynamics of glucose-insulin in the body and, on the other hand, to
enhance the treatment through an ad hoc therapy for the patient. Moreover, continu-
ous glucose monitoring is a breakthrough because it paves the way to the advent of an
artificial pancreas, that is a device capable of reproducing the function of this organ.
In the last 40 years, much work has been done to develop an artificial closed-loop
pancreas able to adjust the insulin infusion in response to glucose changes. In fact,
this kind of device would be less invasive for the subject, being either wearable or
implantable, and automate patient’s action. The first generation of artificial pancreas,
called Biostator, was based on two manipulated variables (glucose and insulin infu-
sion) and programmed to operate minimising hyperglycaemia while avoiding hypogly-
caemia [11]. Nowadays, the frontier is to develop portable devices (wearable artificial
pancreas, WAP), which continuously monitor glucose and provide insulin whenever
required. WAPs typically consist of three parts, as displayed in Figure 1.2:
Figure 1.2. Wearable artificial pancreas components [12].
• a continuous glucose sensor, which detects the glycaemia at regular intervals;
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• a controller, to regulate the insulin infusion rate through the use of control algo-
rithms;
• a continuous insulin pump for its administration, via a cannula inserted under
the skin.
Crucial for a WAP is to have available a reliable physiological model of the glucoreg-
ulatory system, i.e. representing both glucose and insulin dynamics, for the controller
to be able to predict at each time the optimal insulin infusion rate. While the first
devices based on a closed-loop configuration have appeared on market, much efforts
are still addressed to find robust glucose sensors and a reliable control algorithm. The
major challenges remaining are related to sensor calibration errors, unknown meal dis-
turbances, physical activity effect and insulin-glucose sensitivity variability [13].
A major approach in the development of WAP control algorithms is represented by the
use of model predictive control (MPC) strategies, which consist in applying a model to
predict the future output of blood glucose while optimising the future control moves,
namely the insulin infusion. Typically, the objective function to be minimised is the
difference between the desired set point and the blood glucose value estimated by
the model over the prediction time horizon [14]. This fact highlights the necessity of
identifying a reliable model in order to assure optimal performance to the artificial
pancreas.
1.6 T1DM models
An accurate description of the glucose-insulin dynamics in the body is desirable, in
order to make predictions on the behaviour of the subject to possible disturbances,
such as meals or physical exercise.
There are two main categories of mathematical models for the prediction of blood glu-
cose concentration: data-driven models and knowledge-driven models. The former are
empirical models based on a black box approach, that is they consider only input-output
data neglecting any physiology. These models are advantageous over knowledge-driven
ones because of their structural simplicity and low time required for their development.
However, data-driven models lack of any insights on glucose and insulin levels in tis-
sues and organs, since they do not consider any physiological information. On the
other hand, knowledge-driven models take into account the physiological interactions
between glucose and insulin in the glucoregulatory system. Therefore, the effort re-
quired to develop these models is significantly higher, as they usually involve systems
of differential and algebraic equations. The knowledge-driven models can be further
divided into lumped or semiempirical models and comprehensive models. The former
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models entail a limited number of dynamic equations, in which various organs or tis-
sues in the body are lumped into one or more compartments [15]. The latter models
are more complex and require more time for development than lumped models, which
will be examined in detail in the next section.
1.6.1 Lumped physiological models
Bolie was a pioneer in the development of physiological models of the glucoregulatory
system. In 1961, he proposed a linear model based on two differential ordinary differen-
tial equations representing glucose and insulin concentrations, based on his condensed
theory. According to this theory, the liver, pancreas and peripheral tissues commu-
nicate with each other by means of a single compartment through which glucose and
insulin concentration changes are distributed rapidly and uniformly [15]. The limita-
tions of this model are connected with the omission of the action of the kidneys and
intravascular-extravascular differences in concentrations of insulin and glucose.
The most widely known and used model was proposed in 1981 by Bergman et al. [9]
and is generally referred to as minimal model. It was originally developed to measure
insulin sensitivity and glucose effectiveness in an IVGTT, but it has gained popular-
ity due to its relative simplicity. In fact, it uses only three differential equations and
a few parameters to describe the effect of insulin on the regulation of glucose. It is
a compartmental model composed of two submodels: one to account for the glucose
disappearance and the other for the insulin kinetics, as shown in Figure 1.3.
Plasma	insulin	 REMOTE	INSULIN	COMPARTMENT	
GLUCOSE	SPACE	 Periphery	Liver	
INSULIN	
DISTRIBUTION	
SPACE	
secre@on	 disappearance	
Figure 1.3. Schematic of compartments in the minimal model: glucose disappearance (above) and
insulin kinetics (below).
Glucose disappearance is characterised by assuming a remote insulin compartment,
where plasma insulin enters and can act effectively on the dispersal of glucose into
the periphery and the liver and on the inhibition of hepatic glucose production. Post-
prandial insulin secretion can be distinguished in a first-phase release, which begins
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within two minutes of the meal consumption and lasts 10-15 minutes and a following
second-phase release, which is responsible for restoring of normoglycaemia. Therefore,
first-phase insulin release is represented as a bolus accessing the plasma compartment
at the time of the glucose injection, whereas the second-phase insulin secretion is de-
scribed by the third differential equation of the model. The minimal model presents
two strong limitations: firstly, it does not allow representing an exogenous insulin in-
jection and, secondly, no description of the rate of glucose appearance after a meal is
permitted. These limitations make the model not suitable for describing the typical
insulin treatment in a T1DM individual.
A more comprehensive model was proposed by Lynch and Bequette (LB model) in
2002 [16], which is in turn derived from Fisher’s model (1991). Fisher’s model is a
modification of the minimal model, where the three differential equations are adjusted
to take into account glucose absorption after a meal. In addition, since it has been
adapted to T1DM, it omits the term of insulin secretion, which is replaced by an ex-
ogenous insulin infusion term. The LB model adds a fourth differential equation to
link blood and subcutaneous glucose concentrations accounting for a first order delay
between them. A schematic of the LB model is presented in Figure 1.4 with the possi-
ble manipulable inputs, i.e. glucose meal and insulin infusion, and measurable outputs,
i.e. glucose and insulin concentrations.
INSULIN	SPACE	 REMOTE	INSULIN	COMPARTMENT	
GLUCOSE	
SPACE	 Periphery	
Liver	
clearance	
Insulin,	I(t)	
Insulin	
infusion,	U(t)	
Gut	
Glucose	meal,	A	
Subcutaneous	
Essues	
Subcutaneous	glucose	
concentraEon,	Gsc(t)	
Blood	glucose	
concentraEon,	
G(t)	
Glucose	
uptake	rate,	
D(t)	
Figure 1.4. Schematic of Lynch-Bequette model with inputs and outputs.
Discrete results were achieved by Lynch and Bequette in the application of the model
to model predictive control, even though lack of representation during food assumption
and nocturnal periods was observed. In 2006, Van Herpe et al. proposed a modified
minimal model whose extended time validity makes it appropriate to control blood
glucose concentration in intensive care unit patients [17]. At the same time, Roy et al.
[18] developed an extended minimal model which considers also free fatty acids, which
play a relevant role in altering the glucoregulatory system and thus are represented
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with an additional differential equation.
Several clinical and in vitro studies have shown that pancreatic insulin secretion follows
rapid small amplitude and slower large amplitude oscillatory behaviour depending on
the glucose infusion [15]. This fact has been considered by Sturis et al. [19] in develop-
ing a new physiological model of six ordinary differential equations and five nonlinear
equations in the attempt to represent the slow oscillations of insulin and glucose. In
2000, Tolic et al. [20] introduced two models of insulin receptor dynamics in the model
of Sturis et al. Later, Bennett et al. recognised that there were three variables in the
model of Sturis et al. to represent the delay of plasma insulin to inhibit hepatic glu-
cose production which had no clinical meaning. Therefore, they simplified the original
model reducing the 6 ODEs to 3 by introducing an explicit time delay [21].
In 2004, Hovorka and Wilinska developed a more detailed model, known as Hovorka-
Wilinska model [22], which permits a better description of the glucoregulatory system,
taking into account also the absorption of subcutaneous short-acting insulin. The
model includes three separate subsystems: one for glucose, one for insulin and one for
insulin action and entails an increased complexity due to the higher number of differ-
ential equations and model parameters. Nevertheless, it has been proved to be effective
for the characterisation of glucose homeostasis.
One of the latest models has been proposed by Dalla Man et al. in 2007 [23] to describe
accurately glucose assumption through an oral meal. The model consists of a glucose
and an insulin subsystem. The glucose subsystem is divided into two compartments:
the first one accounting for glucose masses in plasma and rapidly equilibrating tissues
and the second one in the slowly equilibrating tissues. The insulin subsystem is char-
acterized by a two-compartment model: one considering insulin mass in plasma and
the other in liver. The model was derived using data on normal subjects, thus addi-
tional modifications are required for its extension to T1DM. Moreover, the fact that
it is a mean model must taken under consideration because it could affect individual
prediction capabilities.
1.7 Design of clinical tests for model identification
The importance of having a reliable model of T1DM, when it comes to the design of
an artificial pancreas, has already been stressed above, so now the relation between
physiological models and clinical tests can be discussed.
Standard clinical tests are mainly used for the diagnosis of diabetes so that, based on
their results, it is possible to state if the patient is ill or healthy. Nevertheless, they are
of primary importance also for research purposes, in order to determine the parameters
of physiological models, that is to identify the subject.
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In the preliminary model analysis, the aim is, given a set of candidate models and
some variables to be measured, to determine whether it is possible to design an experi-
ment that allows to univocally identify the parameters of these models (identifiability)
and to distinguish the different model structures from one another (distinguishability).
Structural identifiability is a condition that guarantees that the same input, applied to
the same model and at the same initial conditions, but using different parameter vec-
tors, results in predicted output trajectories not overlying. Distinguishability, instead,
ensures that two different models with different parameter vectors and with the same
input and initial conditions generate two predicted output trajectories not overlying
[24]. Once verified that the proposed model is endowed with structural identifiability
and distinguishability, the identification of model parameters can be examined. Unique
parameter identification depends on several factors: the structure of the model, the
type of data collected in the experiment, sampling times at which data are collected
and the level of input perturbation (oral/intravenous glucose and pattern of subcuta-
neous/intravenous insulin administrations) induced during the clinical test [15]. An
accurate estimation of model parameters results in a model tailored on the individual
subject, which can provide enhanced care therapy, for instance realising a customised
artificial pancreas.
When performing a clinical test, an excitation pattern consisting in a glucose admin-
istration is applied to the subject and, depending on this solicitation and on how the
response is detected, the parameter estimation may be more or less precise. This issue
is not new, since in 1981 Bergman [9] had already pointed it out, stating that the
IVGTT he had analysed could possibly not represent the best stimulus pattern for the
estimation of metabolic parameters. Bergman suggested that using different temporal
patterns for the glucose and insulin administration could improve the process. In fact,
in 1987 he showed that the injection of insulin some time after glucose in the subject
leads to an increased precision in the estimation of the parameters [25].
More recently, the possibility to obtain better parameter estimation using different
tests has emerged. A schematic of the general procedure to be applied is shown in
Figure 1.5. Initially, the test is designed, subject to the contraints to be met, making
use of model-based design of experiments (MBDoE), then the experiment is carried out
and model parameters are identified. Finally, statistical analysis is used to determine
the accuracy of the estimated parameters.
Applying MBDoE techniques allows to design alternative clinical tests, derived from
the standard ones, which can produce relevant improvement on parameter estimation
while meeting also certain constraints. Adopting the Hovorka-Wilinska model, Gal-
vanin et al. [26] have shown that modifications of some standard clinical tests, like the
OGTT and the postprandial, can guarantee more accurate parameter estimation.
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Figure 1.5. Steps to parameters identification using MBDoE procedures.
In this work three variables were optimised subject to safety constraints on the indi-
vidual: carbohydrates content of the meal, insulin infusion rate and sampling times. It
was proved that a statistically satisfactory parameter estimation for the single subject
is achievable through modified clinical protocols, even though some limitations were
encountered, such as excessive length (from 10 to 14h) and a difficult optimisation of
exogenous insulin administration. Galvanin et al. [27] have also investigated the use of
an advanced MBDoE technique that combines the online model-based design of exper-
iments with the backoff-based MBDoE in the design of clinical tests. This approach
allows to use experimental data as soon as they are available to adjust the design and
takes into account the uncertainty associated with model parameters in order to design
an optimally informative and safe test. Although parameter estimation achieved using
this method is satisfactory, there could be some issues related to the duration of the
test and restoration of basal values. Therefore, the need for more viable tests is the
starting point for further investigations on the topic.
In 2014, Laguna et al. [28] have enquired an identification method based on interval
analysis, which takes into account both variability of the subject and model impreci-
sions. The leading criterium of the procedure is the minimisation of a composite cost
index consisting of a glucose envelope width and an Hausdorff distance-based error
with respect to the envelope. Experimental tests showed that this kind of approach
has good prediction capability in average and better identification performances when
the maximum intra-patient variability is stimulated.
The use of continuous glucose monitoring systems (CGMSs) could ease the design
of optimal clinical tests, even though noise in the measurements and formulation of
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the test itself may hinder model identification in this type of approach, as shown by
Galvanin et al. [29].
1.8 Objectives
The objective of this thesis is to devise feasible clinical protocols allowing for a precise
identification of type 1 diabetes models suited to the characteristics of the individual
subject, while meeting constraints related to:
• safety conditions for the subject must be guaranteed, assuring normoglyceamic
values throughout the test and steady basal glucose concentration at the end of
it;
• invasivity on the patient (type of glucose and insulin admnistration) must be
minimised during execution, in order to make the protocol preferable among
other options;
• ease of implementation, which means the test must be not excessively time de-
manding and not too complex to execute, in terms of sampling and glucose and
insulin administration;
• robustness is required, so as to always assure parameter estimation is possible;
• the information content achievable must be maximised in order to identify the
model parameters for the single subject with the greatest possible precision, so
as to endow it with very reliable prediction capability.
All these requirements cannot be met using standard clinical tests because they have
not been designed specifically for this purpose. Nevertheless, based on their structure
a suitable test is to be devised which, regardless of the subject, is capable of assuring
an optimal parameter estimation so as to design feasible customised care solutions.
In order to account for all the features above, a novel approach will be introduced in
this work to simplify the choice of the best protocol among the several options available.
This approach consists in the definition of some heuristic indices, which are related to
the contraints listed above and allow a quick evaluation of the suitability of a designed
clinical test for parameter identification.

Chapter 2
Model-based design of experiments
This chapter deals with the theoretical aspects of model-based design of experiments.
After a preliminary discussion on the MBDoE procedure, the physiological model of
Lynch and Bequette is described in detail. Then, much relevance is given to the
mathematical description of the theory behind the MBDoE approach and the several
options available in the software where it is embedded. Finally, a novel methodology
based on heuristic indices is presented in order to evaluate the designed tests.
2.1 Introduction
State-of-the-art devices for T1DM management, such as the WAPs, require the avail-
ability of reliable physiological models for the description of glucose dynamics. Since
each subject is characterised by its own physiology, a precise identification of its model
parameters needs to be carried out in order to optimise the performance of the control
algorithm, which is responsible for maintaining normogylcaemia. Parameter identifica-
tion relies on the execution of clinical tests to acquire as much information as possible
to achieve this purpose.
The most commonly used clinical protocols have already been discussed in § 1.4; how-
ever, they were not specifically designed with this aim, so their sampling schedule is
often inappropriate. To overcome this drawback, it is useful to adopt a model-based
design of experiments approach, which allows to design new or modified clinical proto-
cols to accomplish the identification task.
MBDoE is a sequential procedure, which consists of three steps:
1. experiment design: based on the preliminary knowledge of the system, the op-
timal sampling schedule is sought while acting on some manipulable variables.
The objective is to maximise the information content derivable subject to some
constraints related to the safety of the patient;
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2. experiment execution: experimental data are collected carrying out the experi-
ment with the optimal conditions obtained in the previous step;
3. parameter identification: based on experimental data and using some estimators,
the identification of the unknown model parameters is performed.
Parameter	
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Is	the	
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Figure 2.1. MBDoE procedure for parameter estimation [26].
2.2 Lynch-Bequette model
In this work the Lynch and Bequette model [16] (also referred to as LB model) is
selected because of its ease in representing the glucoregulatory system compared to
alternative more recent models. Although lumped physiological models, such as the
LB model, are not able to represent the dynamics of glucose at various organ or tissue
levels, they entail a lesser complexity, also in terms of number of parameters, compared
to comprehensive models. In fact, it consists of only 4 differential equations, which are
displayed below:
dG(t)
dt
= −θ1G(t)−X(t)[G(t) +Gb(t)] +D(t) (2.1)
dX(t)
dt
= −θ2X(t) + θ3I(t) (2.2)
dI(t)
dt
= −θ4[I(t) + Ib] + U(t)
Vi
(2.3)
dGsc(t)
dt
=
G(t)−Gsc(t)
5
−Rut (2.4)
A description of the model variables and constants is given in Table 2.1 and 2.2,
respectively.
As pointed out in § 1.6, equations (2.1)-(2.3) are taken from Fisher’s model, whereas
equation (2.4) relates subcutaneous and blood glucose values considering a 5 minutes
delay between them. Examining the system in detail: equation (2.1) describes the
dynamics of blood glucose concentration, equations (2.2) and (2.3) characterise the
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dynamics of insulin, using a variable proportional to insulin in the remote compartment
(X ) and plasma insulin concentration (I ).
Table 2.1. Lynch-Bequette model variables.
Variable Description
G(t) Difference between blood glucose concentration and its basal value [mg/dL]
D(t) Glucose intake velocity after a meal [mg/dL/min]
U(t) Exogenous insulin infusion rate [mU/min]
X(t) Variable proportional to insulin in the remote compartment [mU/L]
Gsc(t) Difference between subcutaneous glucose concentration and its basal value [mg/dL]
I(t) Difference between plasma insulin concentration and its basal value [mU/L]
Table 2.2. Lynch-Bequette model constants.
Constant Description
Vi Insulin distribution volume [L]
Rut Glucose usage velocity [mg/dL/min]
Gb Glucose basal value [mg/dL]
Ib Insulin basal value [mU/min]
The inputs to the model are represented by the glucose meal D(t) and the exogenous
insulin infusion rate U (t). The model, as presented by equations 2.1-2.4, describes an
OGTT, where the meal-absorption dynamics, differently from Fisher, is not modelled
through the exponential form D(t) = A · exp(−0.05t) but using the more accurate
expression proposed by Hovorka and colleagues [22]:
D(t) =
1000 · A · t · exp(−t/tmax,G)
t2max,G ·BW · Vg
(2.5)
where A is the carbohydrate content of the meal expressed in grams and tmax,G repre-
sents the time-of-maximum appearance rate of glucose in the accessible glucose com-
partment. BW and Vg are factors related to the characteristics of the subject: the first
one, accounts for its body weight and the second one, assesses the available glucose
distribution volume.
In this analysis, the following values for the subject have been considered:
BW = 70 kg tmax,G = 20 min Vg = 1.6 dL/kg (2.6)
This choice represents a lean subject, with the same glucose distribution volume re-
ported by Hovorka et al. [22] and a sensible value for the time-to-maximum of glucose
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uptake.
On the contrary, in the IVGTT, glucose is administrated intravenously, thus the expo-
nential term D(t) in equation 2.1 is substituted with the glucose injection, Uv, while
the rest remains unchanged.
The monitored variable is the total glucose concentration, which is given by:
Gtot(t) = G(t) +Gb (2.7)
The values of Gb, Ib and Vi are chosen according to Lynch and Bequette [16]:
Gb = 80 mg/dL Ib = 15 mU/L Vi = 12 L (2.8)
whereas for Rut the value proposed by Sorensen [30] is selected:
Rut = 0.75 mg/(dL ·min) (2.9)
θ1-θ4 represent the model parameters, which allow for the identification of the single
subject metabolic behaviour. A description of the parameters is presented in Table
2.3:
Table 2.3. Lynch-Bequette model parameters.
Parameter Description
θ1 Rate of blood glucose disappearance into liver or periphery [min
−1]
θ2 Insulin disapperance velocity from the remote compartment [min
−1]
θ3 Insulin apperance velocity in the remote compartment [min
−1]
θ4 Insulin disappearance velocity from the insulin space [min
−1]
θ1 is also known as glucose effectiveness (SG) and quantifies the capacity of the glu-
coregulatory system to reduce blood glucose concentration after a meal. Therefore,
this parameter is very relevant for T1DM patients. The ratio θ3/θ2 represents the
sensitivity to insulin (SI), that is the effectiveness of insulin in restoring glucose basal
values. These two parameters are less important in patients affected by T1DM, as they
do not produce insulin on their own.
The design of a feasible clinical protocol for parameter identification represents the
ultimate objective of the present work.
The established LB model can be used to evaluate standard clinical tests but it also
proves useful to design enhanced modified protocols, where the two manipulable vari-
ables (i.e. glucose administration and insulin infusion) allow maximising the obtainable
information content.
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2.3 Optimal model-based design of experiments
This section deals with the theory behind optimal model-based design of experiments.
Firstly, a mathematical description of the general MBDoE problem is provided with
the variables and constraints involved. Secondly, the dynamic optimisation strategy is
tackled with an overview on the main optimisation criteria available.
2.3.1 Mathematical model and constraints
Dynamic models, such as the Lynch and Bequette model, can be represented using a
general form consisting of a system of differential and algebraic equations (DAEs):{
f(x˙(t),x(t),u(t),w, θˆ, t) = 0
yˆ(t) = h(x(t))
(2.10)
where x(t) ∈ <Nx is the vector of time-dependent state variables, u(t) ∈ <Nu and
w ∈ <Nw are the time-dependent and time-invariant vectors control variables, respec-
tively, θˆ ∈ <Nθ is the set of unknown model parameters to be estimated, t is the time,
yˆ ∈ <Ny is the vector of output responses estimated by the model.
Specifically, in the LB model, insulin infusion U(t) represents the time-dependent con-
trol variable and glucose meal A the time-invariant control variable, while the variable
to be measured is the total glucose concentration Gtot(t).
In order to solve system (2.10), a set of initial conditions, i.e. values of the state
variables at time t = t0, is required in the form:{
f(x˙(t0),x(t0),u(t0),w, θˆ, t0) = 0
yˆ(t0) = h(x(t0))
(2.11)
In physiological models, state variables cannot assume any value but need to be con-
strained to assure safety conditions to the patient throughout the experiment. There-
fore, in the design procedure the following safety end-point constraints are imposed
on:
• lower bound of glucose concentration (LB), which is considered an “hard” con-
straint, that is not to be violated, in order to prevent hypoglycemic conditions.
This is mathematically expressed as:
LB −Gtot(t) ≤ 0→ Gtot(t) ≥ LB (2.12)
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but it is implemented in the software as:
dV1
dt
= max(0, LB −Gtot(t)) ≤ 0 (2.13)
where V1 represents the amount of the contraint violation. The first entry of the
function max represents the maximum violation allowed, while the second entry
defines the function on which the condition applies.
• upper bound of glucose concentration (UB), which can be treated either as a
“hard” or a “soft” constraint, since a small violation (V2) is much more tolerable
by the organism. Similarly to equation 2.13, this is implemented in the software
as:
dV2
dt
= max(0, Gtot(t)− UB) ≤ 0 (2.14)
• final glucose concentration, which must be restored within a certain range of the
initial basal value; a 10% deviation from the initial value has been allowed at the
end of the test.
• derivative of the final glucose concentration (Γ):
Γ =
dG
dt
(2.15)
which is an additional requirement to guarantee that the basal glucose value is
not only reached but also maintained at the end of the test, in order for the
patient to be safely discharged. Due to its definition, this constraint is compelled
to be as close as possible to zero. Typical values used in the design phase for
lower and upper bounds of Γ are -0.01 and 0.01, respectively.
In this work, a glucose concentration of 170 mg/dL is selected as upper bound and
60 mg/dL as lower bound.
MBDoE aims at reducing the model parameters uncertainty region by optimising the
experimental settings, which are grouped in the design vector ϕ ∈ <nϕ :
ϕ = {y0,u(t),w, tsp, τ} (2.16)
where y0 is the set of initial conditions on the measured variables, t
sp = [t1, ..., tnsp ]
T
is the vector of sampling times, which defines the times at which the output variables
are measured and τ is the duration of the experiment.
In order to facilitate the solution of the dynamic optimisation problem, some control
vector parametrisation techniques can be adopted to approximate the set of control
variables u(t) over a number of intervals, as shown by Vassiliadis and colleagues [31].
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For instance, in this work a piecewise constant approximation is used for exogenous
insulin infusion, which means that the variables requiring optimisation are:
• the (nsw−1) times at which the insulin profile changes in value, which are collected
in the vector tsw of switching times;
• the nsw values that the control variable assumes before and after a switching
time, which are collected in the vector zsw [32].
Furthermore, due to practical limitations or safety reasons, constraints on maximum
values of insulin infusion rate and on upper and lower duration of switching intervals
are imposed in the design stage.
2.3.2 Objective function and optimisation criteria
The aim of MBDoE is the maximisation of the information content derivable from the
designed test, so as to achieve a statistically satisfactory parameter identification by
optimising the design vector ϕ. In particular, it is the function ψ of the variance-
covariance matrix that needs to be minimised acting on the elements of the design
vector:
ϕopt = arg min{ψ[Vθ(θ,ϕ)]} (2.17)
For a single experiment, the variance-covariance matrix of model parameters Vθ is
defined as:
Vθ(θ,ϕ) = [Σ
−1
θ + Hθ(θ,ϕ)]
−1 (2.18)
where Hθ represents the Fisher information matrix (FIM) and Σθ the preliminary
variance-covariance matrix of model parameters.
For a dynamic system with discrete sampling the FIM, according to the formulation
of Zullo [33], assumes the form:
Hθ(θ,ϕ) =
nsp∑
k=1
Ny∑
i=1
Ny∑
j=1
sijQ
T
i Qj + H
0
θ (2.19)
where sij is the ij-th element of the NyxNy inverse matrix of measurement errors, Qi is
the nspxNθ dynamic sensitivity matrix of the i-th measured response, whose elements
take the form:
Qi =
[
∂yˆil
∂θm
]
l = 1, ..., nsp m = 1, ..., Nθ (2.20)
and H0θ is the prior dynamic information matrix.
Several design criteria have been proposed for the maximisation of the information
matrix. The most known ones are the so called “alphabetical criteria”, which are also
available in gPROMSr:
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• A-optimality: minimises the trace of the variance-covariance matrix Vθ:
ψA(Vθ) =
1
Nθ
Nθ∑
i=1
(νii) (2.21)
where νii represents the elements on the diagonal of the variance-covariance ma-
trix, which are summed because of the definition of the trace. In geometrical
terms, this criterion corresponds to minimising the dimensions of the hyperrect-
angle within which the confidence ellipsoid of model parameters can be inscribed,
as shown in Figure 2.2 (in 2D).
θ1	
θ2	
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D-op)mality	
A-op)mality	
Figure 2.2. Graphical interpretation of the different design criteria used in MBDoE in a 2D case.
• D-optimality: minimises the determinant of the variance-covariance matrix:
ψD(Vθ) = det(Vθ)
1
Nθ (2.22)
This is also known as the minimum volume criterion because it minimises the
volume of the confidence ellipsoid. In 2D this is the equivalent of minimising the
area of the ellipse (Figure 2.2).
• E-optimality: minimises the largest eigenvalue of the variance-covariance matrix:
ψE(Vθ) = max
k=1,...,Nθ
λk(Vθ) (2.23)
The eigenvalues of the variance-covariance matrix represent the lengths of the minor
and major axes of the confidence ellipsoid. Therefore, by minimising the largest eigen-
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value, the design forces the confidence ellipsoid to become as spherical as possible. In
2D it means the ellipse is forced as close as possible to a circumference (Figure 2.2).
2.4 Experimental data generation
Once the optimal design vector ϕopt has been obtained, the following step of the MB-
DoE consists in the experiment execution. At this stage, experimental data need to
be collected from the designed test. However, this is not actually possible because the
test is still in its design phase. For this reason, it cannot be performed in vivo because
safety and effectiveness have not been proved and the optimal conditions obtained from
the model in the design phase could jeopardise the subject in reality. In addition, at
this point data retrieval from a real patient would significantly augment the overall
time required for the sequential design procedure.
Therefore, experimental data are generated in silico using the same physiological model
but with different parameters (parametric mismatch). This procedure consists in the
following steps:
1. sensible perturbations are assigned to the initial parameters used for the ex-
periment design, generating a new set θ = [θ1, θ2, θ3, θ4]
T , which is assumed to
represent the real physiology of the patient. This set is used to simulate the
glucoregulatory response of that subject;
2. glucose concentrations collected at the sampling times obtained from the designed
test constitute the experimental measurements of the simulated patient;
3. some stochastic and ergodic disturbance factors are applied to these measure-
ments, in order to simulate the experimental noise, that is the random errors
that make each repetition of the experiment different from the others. Assuming
that systematic errors are avoided, the stochastic component can be regarded as
normally distributed with zero mean. The general variance model has the form:
σ2i = ω
2
i (yˆ
2
i )
γi (2.24)
where ωi is the standard deviation of the i-th measured response and γi the
heteroschedastic factor. In this work a constant relative variance of 0.033 is
considered according to Galvanin and colleagues [26], thus γ = 1 and equation
2.24 becomes:
σ2i = ω
2
i (yˆ
2
i ) = (0.033Gtot)
2 (2.25)
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2.5 Parameter estimation
The parameter estimation step consists in the identification of the model parameters
in a statistically sound way based on the experimental data collected or generated in
silico. The optimal result of this procedure is a vector that minimises the distance
between experimental data y and model predicted responses yˆ.
2.5.1 Estimators
The most widely used estimators for the evaluation of the model parameters of a
dynamic model are:
• least squares (LS): is the simplest one and is defined as:
ΦLS(y) =
nsp∑
i=1
[
(yi − yˆi)T (yi − yˆi)
]
(2.26)
• weighted least squares (WLS): takes into account the variance-covariance matrix
of measurement errors:
ΦWLS(y,Σ1, . . . ,Σnsp) =
nsp∑
i=1
[
(yi − yˆi)TΣ−1i (yi − yˆi)
]
(2.27)
As suggested by Galvanin [32], the problem associated with LS and WLS is that
they only provide an estimate of model parameters θˆ but no a-posteriori statistics
about their precision.
• maximum likelyhood (ML): considers a probability distribution that allows to
derive the a-posteriori variance-covariance matrix of model parameters, which
makes this approach suitable for MBDoE. For independent and normally dis-
tributed measurement errors, the ML estimator can be expressed according to
Bard [34] as:
ΦML(y,Σ1, . . . ,ΣN) = 2pi
Ny
2
nsp∏
i=1
|Σi|−
1
2 exp
{
−1
2
nsp∑
i=1
[
(yi − yˆi)TΣ−1i (yi − yˆi)
]}
(2.28)
This is also the estimator that gPROMSr uses for the evaluation of model
parameters.
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2.5.2 Assessment of parameter estimates
Parameter estimates need to be evaluated in terms of precision and accuracy. Precision
of the estimate corresponds to enclosing the set of parameters to a restricted confidence
region, whereas accuracy expresses how much close to the true value (which is unknown)
the estimate is.
Precision of the estimates is evaluated by means of confidence intervals, which are
defined as:
Ki(α) = t¯
(1− α
2
, nsp −Nθ
)
· √νii i = 1, ..., Nθ (2.29)
where t¯ represents the upper critical value of a t-distribution with (nsp −Nθ) degrees
of freedom and νii the variance of the i-th parameter, i.e. element of the variance-
covariance matrix. A α% confidence region indicates that if the experiment is repeated
and the parameters are estimated from the new experimental data, their values will
lie in this confidence region with α% probability. Therefore, the confidence intervals
define the bounds of the confidence ellipsoid:
[θˆi −Ki(α); θˆi +Ki(α)] i = 1, ..., Nθ (2.30)
where θˆi is the i-th estimated parameter.
The t-values express the percentage accuracy of the estimated parameters with respect
to the 95% confidence intervals, i.e. t¯(0.95, nsp −Nθ), which are given by:
t¯i =
θˆi
Ki(0.95)
i = 1, ..., Nθ (2.31)
These values need to be compared with the reference t-value obtained from a Student t-
distribution with confidence α and (nsp−Nθ) degrees of freedom. A t-value larger than
the reference one means that the parameter has been accurately estimated, otherwise
a poor estimate has been accomplished.
Accuracy cannot be evaluated directly since the true value of the parameters remains
unknown, instead, the lack-of-fit test is used to assess that the residuals, i.e. difference
between measured output and predicted response, are actually minimised. It consists
in a χ2-test considering the sum of weighted residuals:
SWR =
N∑
i=1
[(yi − yˆi)TΣ−1i (yi − yˆi)] (2.32)
The fitting of the experimental data is adequate and the model represents a good
description of the system if:
SWR < χ2ref (2.33)
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where χ2ref is a reference χ
2 distribution with (nsp −Nθ) degrees of freedom.
2.6 Preliminary analysis of the model
Prior to the design of experiments procedure, an a-priori evaluation of the physiological
model can be performed so as to get some insights on its structure and potential. In
the present work, two preliminary studies are conducted:
• sensitivity analysis,
• information content analysis.
2.6.1 Sensitivity analysis
Sensitivity analysis consists in the assessment of how some variations on the inputs to
the model reflect on the predicted outputs. In the first place, it is a qualitative analysis
aimed at detecting the temporal effect of the variation on some variables, since a
dynamic model is involved. This kind of observation allows, in the case of a parametric
model, to determine which parameters can be more easily identified (for a specific
set of experimental settings) and which, instead, could require a reparametrisation to
facilitate the process. The responses predicted by the model yˆ to a change in the
parametric set θ are collected in the NyxNθ matrix of local sensitivities:
Q(t) =

q1,1(t) . . . q1,Nθ(t)
...
. . .
...
qNy ,1(t) . . . qNy ,Nθ(t)
 =

∂yˆ1(t)
∂θ1
. . .
∂yˆ1(t)
∂θNθ
...
. . .
...
∂yˆNy(t)
∂θ1
. . .
∂yˆNy(t)
∂θNθ
 (2.34)
2.6.2 Information content analysis
Information content analysis in terms of trace of the FIM can be used for an evaluation
of complex systems with a large number of parameters. In this case, the dynamic pro-
file of the trace highlights time periods when the maximum information can potentially
be obtained through sampling.
Alternatively, a different evaluation of the information content can be performed by
comparing continuous and discrete sampling. Continuous cumulative information con-
tent Ic derivable in the entire test can be computed through the integral of the trace
of the FIM:
Ic =
∫ τ
t=0
tr[Hθ(t)]dt (2.35)
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while discrete information content Id is given by considering only the information ob-
tained at sampling times:
Id =
tsp∑
i=1
tr[Hθ(t)]∆t (2.36)
Beyond the gap in value between the two strategies, this analysis can provide interesting
insights on the best time allocation of the samples.
2.7 Software
The entire simulation work presented in this thesis from modelling to experiment design
and parameter estimation is carried out using gPROMSr Model builder 4.1.0 [35]-
[36], which is an advanced modelling software by Process Systems Enterprise Ltd.
gPROMSr is an equation-oriented modelling system used for building, validating
and executing first-principles models. It allows for the simultaneous resolution of large
systems of algebraic and differential equations. Its peculiarity is that it can be applied
to a wide variety of problems: from steady-state simulation to dynamic simulation and
from parameter estimation to model-based design of experiments.
Generation of the noise applied to glucose measurements is made using the function
normrnd of MATLABr R2013a by MathWorksr [37], which produces arrays from
the normal distribution with the specified mean and variance.
2.8 Indices
The main objective of this work is to devise a feasible clinical test for the identification
of T1DM. So far, the attention has been focused on the experiment design procedure,
aimed at estimating the model parameters with the greatest precision.
In order to discriminate among the possible tests the one offering the best performance,
some criteria for the evaluation must be defined. These criteria must take into account,
beyond the information content derivable, the assurance of safety conditions throughout
the execution and feasibility factors for a successful application.
In order to fulfil these requirements a set of 5 heuristic indices is proposed as the
framework for the test design procedure. All indices are normalised, i.e. defined on
a scale ranging from 0 to 1, where the boundary values represent the least and most
desirable one, respectively. This allows a quick comparison among the tests, both to
identify possible improvement factors and to evaluate the best protocol.
Each index is individually presented and discussed in the following sections.
30 Model-based design of experiments
2.8.1 Information content index
It quantifies the information content derivable from a test by means of the discrete
information content (Id), defined by equation 2.36, achieved during the sampling pro-
cedure, by comparing it with the maximum value (Id,max) obtained among all the tests
analysed at a given parametric set. Mathematically, it is expressed as:
γ =
Id
Id,max
(2.37)
2.8.2 Invasivity index
It is an attempt to quantify the impact of the glucose and insulin administration strate-
gies on the subject. Compared to the other indices, it is more tricky to define because
it depends on the tolerance of the individual.
A basic difference between the OGTT and the IVGTT lies in glucose administration:
for the first it is oral, while for the second it is intravenous.
In terms of insulin administration, several pathways exist: the most used is subcu-
taneous delivery because it allows continuous infusion and it is less invasive (since it
involves the subcutaneous layer) than intravenous injection, which is normally utilised
just for surgery or complications. A third preferable route is oral delivery, which is a
non-invasive method but it still requires studies due to insulin lack of permeability in
the intestinal epithelium [38].
Invasivity index has been assessed through the following equation:
α = 1− αglucose + αinsulin
2
(2.38)
where the factors αglucose and αinsulin may assume the values: 0 for oral administration,
0.5 for subcutaneous (only for insulin administration) and 1 for intravenous.
2.8.3 Safety index
This index takes into account the violations of glucose upper and lower bounds observed
during the entire duration of the test in terms of areas. As already pointed out, upper
and lower bound violations are to be treated differently because of their different impact
on the subject. Thus, the total violation β′ is calculated using a weighting factor:
β′ = V1 + 0.5V2 (2.39)
where V1 and V2 represent the violations of glucose lower and upper bounds, respec-
tively.
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However, since the sought value should lie in the range from 0 to 1, applying normali-
sation the safety index β becomes:
β = 1− β
′
βmax
(2.40)
where β′ is the total violation of the test considered and βmax the maximum violation
observed over all the tests analysed at a given parametric set.
2.8.4 Sample index
This index accounts for the overall number of samples which are collected during the
test execution. A maximum of 60 samples (nmax) collected is considered, assuming
to apply a discrete sampling schedule to the OGTT (whose duration is 2 h) with a
minimum time between measurements of 2 min. Therefore, the index results:
pi = 1− nsp
nmax
(2.41)
2.8.5 Duration index
This index considers the time horizon for the execution of the test. As a reference,
a maximum duration of 12 h (tmax), corresponding to the length of a day hospital, is
assumed for its completion, that is taking into account the time required to restore and
maintain the glucose basal value of the subject. Therefore, the index is simply defined
as:
τ = 1− ttest
tmax
(2.42)

Chapter 3
Preliminary analysis of the model
This chapter deals with the preliminary evaluation of the Lynch and Bequette model
by means of two clinical tests. Firstly, the two reference tests adopted in this work
are described, in terms of schedule and inputs to the model. Secondly, sensitivity
analysis is applied to the model to investigate how it responds to small variations in
the input of glucose and in model parameters using the two standard protocols. Finally,
a comparison is made of the cumulative information content derivable from the model
using the standard tests with discrete and continuous sampling.
3.1 Standard clinical tests
In § 1.4 the structure of the main standard clinical tests has already been discussed.
The present work is concerned with only two of them: the Oral Glucose Tolerance Test
and the Intravenous Glucose Tolerance Test, which are considered the framework for
the development of optimised protocols.
As outlined by the WHO, the OGTT entails only two glucose samples, which are clearly
insufficient for model identification purposes. Because of this and the unfeasibility to
restore glucose basal value within the 2 h duration (using 2 U of insulin), a different
protocol for the OGTT has been considered. This modified protocol, proposed by Dalla
Man and coworkers [39], consists in a 5 h test using the same glucose administration
but collecting 11 samples at times: 0, 10, 20, 30, 60, 90, 120, 150, 180, 240 and 300 min.
From now on, this test will be referred to as standard OGTT. In the case of the OGTT,
the LB model, described in § 2.2, has two control variables: glucose administration and
insulin infusion. For the standard OGTT, the glucose meal amounts to 75 g and the
insulin infusion rate is kept constant at 16.666 mU/min [16], which corresponds to a
total of 5 U.
The schedule of the IVGTT is maintained unchanged, as described in § 1.4, with 23
samples collected at the sampling times prescribed by Bergman [9] over the 182 min
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duration of the test. The so established protocol will be referred to as standard IVGTT.
Similarly to the OGTT, there are still two control variables in the model: glucose
injection and insulin infusion. For the IVGTT, the term representing the glucose meal
D(t) in equation 2.1 of the LB model is replaced by the glucose injection Uv. Following
the guidelines of this test, a glucose injection of 300 mg/kg over a 1 min interval is
performed at time t=0, which means the term Uv corresponds to:
Uv =
300 mg/kg ·BW
1 min · Vg ·BW =
300 mg/kg
1 min · 1.6 dL/kg = 187.5
mg
dL ·min (3.1)
In the same way as the OGTT, insulin infusion rate is maintained constant at 16.666 mU/min
so, due to the shorter duration of the IVGTT, the total amount of insulin is reduced
to 3033 mU.
The initial set of parameters θ0 for the model has been chosen according to Lynch and
Bequette, as shown in Table 3.1.
Table 3.1. Initial set of parameters θ0 for the LB model.
Parameter Value [min−1]
θ1 0.028735
θ2 0.028344
θ3 5.035 ·10−5
θ4 5/54
3.2 Sensitivity analysis
3.2.1 Sensitivity to glucose administration
Firstly, sensitivity analysis has been carried out on the control variable regarding glu-
cose meal/injection. The input of glucose A expressed in grams has been increased of
10% in the standard OGTT (Figure 3.1) and, similarly, the glucose injection has been
augmented of 10% in the standard IVGTT (Figure 3.2). In both cases, the output
variable of interest is the glucose concentration Gtot, because it is the measured vari-
able in the experiments to be designed and, more importantly, it is the variable that
needs to be controlled in the patient.
Figure 3.1 and 3.2 show a first important difference between the two standard proto-
cols on the glucose profile due to the type of glucose administration. In the standard
OGTT, the oral glucose assumption is modelled with the exponential equation 2.5 and
this results in a delayed smooth peak. On the contrary, in the standard IVGTT the
intravenous glucose injection produces an immediate spike.
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Additionally, in both cases the effect of the glucose change in input is concentrated on
the spike of the curve and its proximity and softens when moving away from it.
As a further consideration, the amount of insulin administered is insufficient for both
the standard protocols to prevent violations of glucose upper bound, even though basal
glucose values are restored at the end of them.
Figure 3.1. Sensitivity of glucose concentration Gtot to a 10% increase in the glucose meal A in a
standard OGTT.
Figure 3.2. Sensitivity of glucose concentration Gtot to a 10% increase in the glucose injection Uv
in a standard IVGTT.
3.2.2 Sensitivity to model parameters
In the second place, sensitivities of glucose concentration to model parameters have
been individually tested upon a 10% increase in their values. Sensitivity matrix is
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calculated according to formula 2.34, whose elements, considering only one output (i.e.
Gtot), can be expressed as:
qi =
Gtot(θ
′
i)−Gtot(θi)
θ
′
i − θi
· θi i = 1, . . . , Nθ (3.2)
where θi and θ
′
i represent the original and perturbed sets of parameters, respectively,
and Gtot(θ
′
i) and Gtot(θi) the corresponding responses of the model.
The results are presented in Figure 3.3 for the standard OGTT and 3.4 for the standard
IVGTT.
(a) (b)
(c) (d)
Figure 3.3. Standard OGTT sensitivity analysis to a 10% increase in model parameters: θ1 (a), θ2
(b), θ3 (c) and θ4 (d).
Peaks exhibited in sensitivity indicate zones where the larger deviations due to the
parameter change are observed, hence where the maximum information content of that
specific test can be extracted.
For the standard OGTT, glucose sensitivities to the parameters show spikes distributed
in the times ranging from 75 to 125 min. Looking back at Figure 3.1, it can be observed
that this temporal distribution corresponds to the period following the maximum in
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glucose concentration occurring after a meal. It is worth noting that glucose sensitiv-
ities to θ2 and θ3 are 4 orders of magnitude lower than those of the other parameters
due to fact that they are not closely related to glucose dynamics.
(a) (b)
(c) (d)
Figure 3.4. Standard IVGTT sensitivity analysis to a 10% increase in model parameters: θ1 (a), θ2
(b), θ3 (c) and θ4 (d).
Figure 3.4 shows glucose sensitivities to model parameters for a standard IVGTT.
A peak due to glucose injection is observed around 30 min for θ1 (a), which is related
to glucose effectiveness, and thus is anticipated compared to the OGTT because of the
faster response induced by the injection. Similarly to the OGTT, glucose sensitivities
to θ2 and θ3 (b, c) are 4 orders of magnitude lower than the other parameters. Apart
from θ1, sensitivities to the other parameters present an asymptotic behaviour, which
makes it harder to locate the best sampling zone but also indicates that the information
may theoretically be extracted over a longer period.
Finally, it is interesting to note that the highest sensitivity values in the standard
OGTT, i.e. for θ1 and θ3, are more than double of the same sensitivities in the standard
IVGTT. This fact can be interpreted as a hint of the higher potentiality of the OGTT
regarding the information content derivable.
38 Preliminary analysis of the model
3.3 Information content analysis
The information content theoretically derivable through the standard OGTT and
IVGTT has been inquired comparing the continuous and discrete information, which
are computed using equations 2.35 and 2.36. Additionally, in order to evaluate the
effect of an increase in the number of samples, the effect of the sampling schedule of
the standard tests has been compared to 50 time-equispaced samples.
Final data of the cumulative information content from the standard tests with regular
and augmented sampling are presented in Table 3.2, while graphical comparisons of
the cumulative information content are plotted in Figure 3.5-3.6.
Table 3.2. Cumulative information content of standard OGTT and IVGTT: continuous versus
discrete sampling.
Test Discrete sampling Continuous sampling
OGTT 11 samples 150.06 2.89 · 105
50 samples 963.94 2.89 · 105
IVGTT 23 samples 125.23 8.66 · 104
50 samples 475.93 8.66 · 104
From Table 3.2, it is clear that the OGTT compared to the IVGTT allows for an
higher information content to be reached both in the continuous and discrete sampling.
The reason for this lies in the different type of stimulus induced on the patient: the
OGTT uses a meal which is more physiological than an injection. In addition, the
OGTT induces an higher violation of glucose upper bound, that is responsible for a
greater information gain during the test.
The information content significantly decreases (3 orders of magnitude) from the con-
tinuous to the discrete sampling, while, as it is easily deducible, increasing the sampling
frequency a greater discrete information can be achieved. Theoretically, by increasing
the number of samples to infinite the information content achieveable reaches the same
realised with a continuous sampling strategy.
Figure 3.5 shows that, in the OGTT, the rise in the sampling frequency (b), especially
in the first 100 min where the height of the steps is higher with the standard sampling
(a), is responsible for the final higher value.
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(a) (b)
Figure 3.5. Cumulative information content from the OGTT with standard, i.e. 11 samples (a), and
increased sampling, i.e. 50 samples (b), compared to the continuous one.
On the contrary, Figure 3.6 displays how in the IVGTT the overall discrete infor-
mation content enhancement is less evident than the OGTT due to the better temporal
distribution of the samples, which results in a more uniform increase of the information
at each step.
(a) (b)
Figure 3.6. Cumulative information content from the IVGTT with standard, i.e. 23 samples (a),
and increased sampling, i.e. 50 samples, compared to the continuous one.

Chapter 4
Designed clinical tests
This chapter represents the core of this thesis because it deals with the design of clini-
cal tests for the identification of physiological models complying with some safety and
feasibility requirements.
Firstly, the assumptions made in the design phase and in the following parameter
estimation task are discussed. Secondly, the inadequacy of the two standard proto-
cols presented in Chapter 3 is shown and the designed clinical tests are individually
addressed, both in terms of design and parameter estimation capability. Finally, a
comparison is made among the designed tests to assess their overall performance by
means of the heuristic indices previously introduced.
4.1 Introduction
In this chapter the design of clinical protocols using a model-based design of experi-
ments approach is tackled. The objective is to devise an optimal test procedure for the
identification of model parameters in subjects affected by T1DM.
Based on the Lynch and Bequette model, described in § 2.2, the following tests have
been designed and will be discussed:
• 5h-11s oral test: an oral test with one meal, a duration of 5 h and 11 samples
taken;
• 5h-22s oral test: similar to the previous one, but with 22 samples collected;
• 5h-22s-2m oral test: an oral test with two meals, a duration of 5 h and 22 samples
taken;
• 3h-23s intravenous test: an intravenous test with one glucose injection, a duration
of 3 h and 23 samples collected;
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• 3h-23s-2i intravenous test: similar to the previous one, but with two glucose
injections.
The reason why these tests are presented will be pointed out in the chapter as soon as
they are introduced.
Beyond the settings applied for their design and schedule obtained for the execution, the
tests will be characterised based on their identification capabilities. For this analysis,
two different parametric sets have been chosen: one involving a moderate and the other
a severe change with respect to the design parametric set.
4.1.1 Parametric sets
The values of the model parameters previously reported in Table 3.1 refer to a healthy
subject. Taking those parameters as a reference, the set has been normalised and from
now on it will be indicated as Θ0 = [1, 1, 1, 1]
T . This set has been considered as the
starting point for the design procedure of all the tests presented in this work because
the purpose is not just to identify a population of diabetic subjects. On the contrary,
the protocol should ideally be able to identify every possible individual, assuming that
no a-priori information on the severity of his/her illness is available.
In addition, two different parametric sets are taken into account for assessing the
parameter estimation performance of the designed tests. Set Θ1 considers a slightly
diabetic patient, while set Θ2 describes a subject with a more severe condition. Both
sets are normalised with respect to the parameters of the healthy subject and reported
in Table 4.1.
Table 4.1. Parametric sets used for the parameter estimation task.
Parametric set Values [min−1]
Θ1 [0.8, 1.2, 0.8, 1.2]
T
Θ2 [0.6, 1.4, 0.6, 1.4]
T
Two aspects have been examined for the choice of these two parametric sets:
• sensible deviations from the healthy subject set, so as to reproduce a hypotetical
T1DM patient;
• different degrees of deviation, i.e. a moderate and a severe change, in order to
compare and contrast the parameter estimation capability of different designed
tests.
Typical values of the parameters have been found in literature [9] for lean subjects
with a low glucose tolerance. In terms of parameter values, this primarily reflects in
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a decrease of the first and third parameter and an increase of the fourth one. In fact,
the first parameter represents the rate of blood glucose disappearance into liver or
periphery, also known as glucose effectiveness. This capacity is highly compromised
in diabetic patients. The third parameter represents insulin appearance velocity in
the remote compartment, where it is effective in accelerating glucose disappearance.
Typically, the value of this parameter in diabetic patients is significantly lower than
healthy subjects due to the deficiency of their glucoregulatory system. The rate of
insulin disappearance from the insulin space, represented by the fourth parameter,
undergoes a substantial increment, since there is no endogenous insulin production in
a T1DM patient. The second parameter has been somehow overestimated in set Θ2,
in order to investigate the identification performance of the designed protocols.
4.1.2 Design assumptions
In all the tests performed, it is assumed to measure blood glucose concentration. The
number of samples collected is not subject to optimisation, but only their temporal
allocation. A minimum distance of 5 min between measurements is assigned to the oral
tests, according to Galvanin et al. [26]. In the intravenous tests, the distance is reduced
to 2 min as in the standard IVGTT, because of the shorter duration and different kind
of stimulus induced in the subject.
A minimum duration of 5 min is selected for the insulin infusion intervals. However,
a higher value is often imposed so as to obtain a protocol easier to be implemented,
hence reducing the complexity of execution.
The lower bound is a “hard” constraint, thus its violation is not allowed, while the
upper bound is a “soft” constraint, hence small violations are sometimes tolerated.
As regards the other end-point constraints, the final glucose concentration needs to
be restored within a ± 5% range of the basal value (i.e. 80 mg/dL). Additionally, the
derivative of the final glucose concentration needs to be as close as possible to zero, so
as to assure the conservation of the basal value.
Finally, a calculation of the typical insulin requirement per meal is performed, in order
to allow for a comparison with the design results. For adult T1DM patients, an insulin
value of 0.54 U/kg/d has been found in literature [40], which corresponds to 37.8 U/d
for a 70 kg person. It is assumed that the daily calorie need for a person is equivalent to
2000 kcal/d and 55% is introduced as carbohydrates, as recommended by the Food and
Agriculture Organization of the United Nations [41]. This is equivalent to an intake
of 1100 kcal/d from carbohydrates. Glucose and sugars in general provide 3.75 kcal/g
[41], hence approximately 295 g of carbohydrates are daily required:
1100 kcal/d
3.75 kcal/g
= 293.3 g/d ≈ 295 g/d (4.1)
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Based on this value, the amount of insulin required by the patient in a standard OGTT
can be computed through the following proportion:
37.8 U/d : 295 g/d = x : 75 g → x = 9.61 U (4.2)
Similarly, in a standard IVGTT, which entails a 21 g glucose administration, the esti-
mated insulin needed corresponds to 2.69 U.
4.2 Standard OGTT
This test has already been presented in Chapter 3 and analysed with some preliminary
sensitivity studies on the glucose assumption and on the model parameters. It consists
of a 5 h test during which 11 blood samples are taken at the times reported in Table 4.2.
Table 4.2. Sampling times for the standard OGTT.
Variable Value
tsp [min] [0, 10, 20, 30, 60, 90, 120, 150, 180, 240, 300]
Insulin is perfused at a constant rate of 16.666 mU/min, as stated by Lynch and
Bequette [16].
This protocol has not been obtained through a design of experiments procedure, hence
it is not optimised. Therefore, it is interesting to enquire how informative this protocol
is.
Figure 4.1 shows the glucose profile of the healthy subject (i.e. set Θ0) and the one
obtained after parameter identification with set Θ1. It is worth noting the great
mismatch between the two curves, especially after the peak of glucose has been reached
on. This gap is due to the influence of the parameters on the response that, in the case
of a diabetic patient, causes a significant increment of glycemia.
In terms of safety, it is clear how this protocol jeopardises the patient. In fact, despite
the upper bound is not a hard constraint, glucose concentration of the subject heavily
exceeds this limit for about two hours.
Safety could be improved through an optimisation of the insulin infusion profile. In
particular, it can be noticed that the current amount of insulin administered (i.e. 5 U)
is far below the reference value computed in Equation 4.2 for such a glucose meal.
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Figure 4.1. Glucose profiles of the standard OGTT for the healthy subject (i.e. with set Θ0) and
after identification with set Θ1.
From Table 4.2, it is evident that the estimated parameters are far from the true
values. In effect, this non-optimised protocol provides statistically unsatisfactory esti-
mates, as it is proved by the t-values, which are all well below the reference one.
Table 4.2. Parameter estimation statistics for the standard OGTT with set Θ1 (asterisks denote t
values failing the t-test).
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.895)
Θ1 0.7775 1 0.700 1.111*
Θ2 0.6650 1 6.480 0.103*
Θ3 3.9925 1 3694 0.001*
Θ4 1.0212 1 20.13 0.051*
Table 4.3 highlights that also the fitting of the experimental data is inadequate,
thus this test cannot be used for identification purposes with the current schedule.
Table 4.3. Lack of fit test for the standard OGTT with set Θ1 (asterisk indicates a bad fit).
Weighted residual χ2-value (95%)
27.3241* 14.0671
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4.3 Standard IVGTT
This test has a duration of 182 min and entails the collection of 23 blood samples with
the schedule reported in Table 4.4.
Table 4.4. Sampling times for the standard IVGTT.
Variable Value
tsp [min] [2, 4, 6, 8, 10, 12, 14, 16, 19, 22, 27, 32, 42,
52, 62, 72, 82, 92, 102, 122, 142, 162, 182]
Similarly to the standard OGTT, the insulin infusion rate is constant and equal to
16.666 mU/min. This results in an overall insulin infusion slightly greater (i.e. 3.03 U)
than the value estimated for such a glucose assumption.
Figure 4.2 shows the glucose profiles with set Θ0 and after identification with set Θ1.
A sharp spike is observed with a lower maximum than the standard OGTT and a
relatively reduced violation of the upper bound.
Figure 4.2. Glucose profiles of the standard OGTT for the healthy subject (i.e. with set Θ0) and
after identification with set Θ1.
From an a-priori evaluation, as a consequence of the higher number of samples
collected, an enhanced identification capability would be expected compared to the
standard OGTT. However, in Table 3.2 it has already been pointed out that the stan-
dard OGTT provides a higher information content despite its lower number of samples.
This fact reflects on the parameter estimates reported in Table 4.5. Only the first pa-
rameter can be estimated satisfactorily, while no estimate is obtained for the second
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one. The other two parameters present completely unreliable values, as it is showed
by the huge confidence intervals associated with them.
Table 4.5. Parameter estimation statistics for the standard IVGTT with set Θ1 (asterisks denote t
values failing the t-test).
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.725)
Θ1 0.6336 1 0.111 5.707
Θ2 0 1 - -
Θ3 0.3507 1 143.5 0.002*
Θ4 1.0559 1 214.06 0.044*
Finally, Table 4.6 shows that a bad fit of the experimental data is still obtained.
Table 4.6. Lack of fit test for the standard IVGTT with set Θ1 (asterisk indicates a bad fit).
Weighted residual χ2-value (95%)
48.4254* 31.4104
4.4 5h-11s oral test
This first designed protocol aims at optimising the standard OGTT applying a MBDoE
approach. It maintains the same duration and number of samples, trying to extract as
much information as possible while controlling the insulin infusion rate.
4.4.1 Experiment design
The sampling times adopted for the standard OGTT are not the result of an optimi-
sation, hence they do not allow to maximise the information content achievable during
the test. Therefore, it makes sense to apply the design of experiments to devise the
best temporal allocation of the samples to be collected, using insulin infusion as the
control variable. Table 4.7 reports the settings imposed in the design phase to the
manipulated variable.
48 Designed clinical tests
Table 4.7. Controlled variable settings for the 5h-11s oral test design of experiment.
Insulin settings Value
Control type piecewise-constant
Intervals number 4
Interval lower bound [min] 5
Upper bound [mU/min] [150,115,115,115]
Furthermore, the test is required to be safe for the subject, thus the end-point
constraints displayed in Table 4.8 have been enforced in order to ensure that kind of
design. On the one hand, the constraints on the upper and lower bound violations
aim at assuring harmless conditions during the execution. On the other hand, the
constraints on the final glucose concentration and its derivative force to restore the
basal values of the patient prior to the test.
Table 4.8. End-point constraints for the 5h-11s oral test design of experiments.
Constrained variable Lower bound Upper bound
Lower bound violation [mg · min/dL] -0.1 0.1
Upper bound violation [mg · min/dL] -0.1 0.1
Gtot [mg/dL] 76.0 84.0
Γ [mg/(dL · min)] -0.01 0.01
The result of the MBDoE procedure is shown in Figure 4.3, in terms of glucose
profile obtained (a) and insulin infusion schedule (b). Firstly, it is clear how the design
allows to enclose the glucose profile between the lower and upper bound, thus max-
imising the safety of the patient, at least with this parametric set. However, it could
endanger a different subject, i.e. having a highly different parametric set. Secondly,
a simple insulin administration profile is obtained, since insulin needs to be perfused
only in two of the four control intervals.
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(a) (b)
Figure 4.3. 5h-11s oral test: glucose profile from the MBDoE procedure (a) and insulin administra-
tion profile (b).
Table 4.9 collects the detailed results of the optimisation. The first thing to notice
is the information content improvement accomplished thanks to the optimisation, since
index Id increases from 150 to 268.
Unfortunately, the main issue of this test is related to the excessive insulin infusion
rate required in its initial part. This value is beyond those reported in literature for
the available insulin infusion devices. Therefore, this test is only meant to show the
enhancements permitted by a MBDoE approach over the standard OGTT.
Table 4.9. Optimised design variables and discrete information content for the 5h-11s oral test.
Variable Value
tsp [min] [0, 38, 43, 48, 123, 128, 222, 227, 232, 295, 300]
U [mU/min] [149.99, 0, 23.82, 0]
tU [min] [39.52, 148.01, 95.46, 17.01]
Id 268.00
4.4.2 Parameter estimation
Parameter identification has been performed using sets Θ1 and Θ2. Looking at Figure
4.4, a significant mismatch is evident between the designed and the identified profiles,
which increases as the gap in the corresponding parametric sets rises. This behaviour,
on the one hand, moves the subject away from the lower bound but, on the other hand,
causes a modest violation of the upper bound.
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(a) (b)
Figure 4.4. Glucose profiles from the MBDoE procedure and after identification with set Θ1 (a) and
Θ2 (b) for the 5h-11s oral test.
The estimates of the parameters are statistically satisfactory for both the sets used,
as shown in Table 4.10 and 4.11. This means that the optimisation strategy adopted is
actually effective in devising a protocol capable of increasing the information content
achievable.
Table 4.10. Parameter estimation statistics for the 5h-11s oral test with set Θ1.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.895)
Θ1 0.6469 1 0.1836 3.524
Θ2 1.3089 1 0.1799 7.274
Θ3 0.7439 1 0.0637 11.68
Θ4 1.0630 1 0.1703 6.242
Table 4.11. Parameter estimation statistics for the 5h-11s oral test with set Θ2.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.895)
Θ1 0.4716 1 0.1814 2.600
Θ2 1.4866 1 0.2784 5.340
Θ3 0.5517 1 0.0860 6.419
Θ4 1.1534 1 0.3461 3.332
4.5 5h-22s oral test
This test attempts to maintain the positive aspects observed in the 5h-11s oral test,
such as the good estimation capabilities, while getting rid of the unfeasible insulin
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infusion rate used in that test.
4.5.1 Experiment design
In this optimisation, the number of samples is risen to 22, so as to furtherly increase
the information derivable. This is a sensible value because it is close to the number of
samples taken in the standard IVGTT, but distributed over a longer time period.
Similarly to the 5h-11s oral test, only insulin infusion is considered as control variable
in the design. However, the maximum on the upper bound is fixed at 100 mU/min,
according to Lynch and Bequette [16], and the control intervals reduced to 3, as shown
in Table 4.12.
Table 4.12. Controlled variable settings for the 5h-22s oral test design of experiment.
Insulin settings Value
Control type piecewise-constant
Intervals number 3
Interval lower bound [min] 30
Upper bound [mU/min] [100, 90, 90]
The end-point constraints are partially relaxed. In fact, due to the lower insulin in-
fusion rate imposed, a small violation of the upper bound needs to be permitted (Table
4.13), for the optimisation to converge. Additionally, the constraint on the derivative
of the final glucose concentration is loosened, so as to keep the duration of the test
unchanged.
Table 4.13. End-point constraints for the 5h-22s oral test design of experiment.
Constrained variable Lower bound Upper bound
Lower bound violation [mg · min/dL] -0.1 0.1
Upper bound violation [mg · min/dL] -0.1 500
Gtot[mg/dL] 76.0 84.0
Γ [mg/(dL · min)] -0.1 0.1
The glucose and insulin profiles obtained applying the MBDoE procedure are shown
in Figure 4.4. It can be noticed that allowing for a small violation of the upper bound
prevents glucose concentration from hitting the lower bound. Insulin infusion profile is
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even simpler than the 5h-11s oral test and also the amount of insulin perfused decreases
from 8.2 U to 6.1 U.
(a) (b)
Figure 4.4. 5h-22s oral test: glucose profile from the MBDoE procedure (a) and insulin administra-
tion profile (b).
The settings obtained for the test, as the sampling times, control variable values
and switching times are displayed in Table 4.14. Furthermore, the discrete information
content exhibits a huge increment as a consequence of the rise in samples.
Table 4.14. Optimised design variables and discrete information content for the 5h-22s oral test.
Variable Value
tsp [min] [0, 17, 22, 27, 82, 97, 102, 107, 112, 117, 154, 182,
190, 195, 200, 213, 218, 254, 261, 290, 295, 300]
U [mU/min] [96.31, 0, 18.59]
tU [min] [30, 95.83, 174.17]
Id 455.57
4.5.2 Parameter estimation
The effect of the parametric mismatch is relevant (Figure 4.5), especially for set Θ2
(b), which shows a remarkable violation of the upper bound. This represents a poten-
tially harmful condition for the patient, hence it needs to be handled if the test is to
be applied on a clinical scale.
Additionally, it should be observed that in both cases it is difficult to obtain a stable
end-point glucose concentration, i.e. a zero derivative.
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(a) (b)
Figure 4.5. Glucose profiles from the MBDoE procedure and after parameter identification with set
Θ1 (a) and Θ2 (b) for the 5h-22s oral test.
The effect of the samples rise is numerically evident also by the estimates achieved,
presented in Table 4.15 and 4.16. In fact, the t-values associated with the estimated
parameters are greater than those reported for the 5h-11s oral test for both sets. This
means higher precision in the identification, as it is also proved by the reduction of the
confidence intervals.
Table 4.15. Parameter estimation statistics for the 5h-22s oral test with set Θ1.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.734)
Θ1 0.7738 1 0.0964 8.031
Θ2 1.2316 1 0.1680 10.05
Θ3 0.8117 1 0.1360 5.969
Θ4 1.1566 1 0.0877 13.19
Table 4.16. Parameter estimation statistics for the 5h-22s oral test with set Θ2.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.734)
Θ1 0.6038 1 0.1024 5.897
Θ2 1.4844 1 0.2348 6.322
Θ3 0.6533 1 0.1935 3.376
Θ4 1.4164 1 0.2156 6.569
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4.6 5h-22s-2m oral test
The objective of this design is to avoid or at least reduce the violation of the glucose
upper bound, so as to increase the safety of the test. This can be accomplished, for
instance, by administering multiple glucose meals with a reduced amount of glucose in
each one.
4.6.1 Experiment design
The design of this protocol departs from the positive results obtained from the oral
tests previously devised, in terms of parameter estimation performance. The number
of samples taken is maintained at 22, so as to possibly reproduce the high information
content previously achieved. The oral administration of glucose is kept as well, but
it is splitted into two different meals of reduced quantity, which are to be optimised.
Therefore, in addition to the insulin infusion rate, two other control variables can be
adjusted: the amount of glucose of each meal and the meal times. The amount of
glucose per meal is enclosed between 10 and 30 g, while the meal times are chosen so
as the first one occurs at t=0 min and the second one can move in the range from 100
to 150 min. Differently from insulin infusion, these two variables are time-invariant.
The settings used for the manipulated variables in the design are reported in Table 4.17.
Table 4.17. Controlled variable settings for the 5h-22s-2m oral test design of experiment.
Insulin infusion Glucose amount Meal times
Control type piecewise-constant time-invariant time-invariant
Intervals number 3 1 1
Interval lower bound 20 min - -
Lower-Upper bounds 0-50 mU/min 10-30 g [0-1, 100-150] min
Since the aim is to improve the safety of the protocol, stricter limits have been
imposed on the design not tolerating any violation at all (Table 4.18).
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Table 4.18. End-point constraints for the 5h-22s-2m oral test design of experiments.
Constrained variable Lower bound Upper bound
Lower bound violation [mg · min/dL] -0.01 0.01
Upper bound violation [mg · min/dL] -0.01 0.01
Gtot [mg/dL] 76.0 84.0
Γ [mg/(dL · min)] -0.01 0.01
The design result, shown in Figure 4.6, allows to avoid any violation of the upper
bound and, at the same time, to assure a higher stabilisation of the final glucose con-
centration.
(a) (b)
Figure 4.6. 5h-22s-2m oral test: glucose profile from the MBDoE procedure (a) and insulin admin-
istration profile (b).
The two peaks that are observed are due to the two meals, which also produce a
different type of insulin infusion profile from those observed in the previous tests. In
fact, the maximum insulin infusion rate is located in the central interval because of the
second meal.
Table 4.19 exhibits the detailed results of the optimisation. It can be observed that
the second meal has the effect of concentrating the samples in the last 100 min of the
test. The overall amount of glucose administered to the patient has been reduced to
51 g, even though the total amount of insulin perfused has been scarcely decreased to
5.8 U.
The discrete information content derived at the design conditions is only slightly re-
duced compared to the 5h-22s oral test, hence the parameter identification should still
be satisfactory.
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Table 4.19. Optimised design variables and discrete information content for the 5h-22s-2m oral test.
Variable Value
tsp [min] [0, 79, 84, 89, 94, 145, 150, 155, 160, 202, 207, 212,
217, 222, 227, 232, 275, 280, 285, 290, 295, 300]
U [mU/min] [10.57, 33.34, 16.78]
tU [min] [114.87, 87.20, 97.94]
Meals [g] [21.09, 30.00]
tmeals [min] [0, 150]
Id 431.56
4.6.2 Parameter estimation
From Figure 4.7, the result of the identification with set Θ1 (a) by means of the 5h-22s-
2m oral test appears to be quite good in terms of safety. A small violation of the upper
bound is observed and glucose final concentration is not too far from its basal value.
Unfortunately, the identification performed with set Θ2 (b), emphasises the limitation
of this protocol. In fact, the final glucose concentration is too distant from the basal
value and the final derivative is not stable yet, thus making the test unsuitable for
clinical applications.
(a) (b)
Figure 4.7. Glucose profiles from the MBDoE procedure and after identification with set Θ1 (a) and
Θ2 (b) for the 5h-22s-2m oral test.
Parameter estimates are satisfactory with both sets (Table 4.20 and 4.21), even
though not as good as those realised in the 5h-22s oral test, as it can be observed
comparing the t-values.
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Table 4.20. Parameter estimation statistics for the 5h-22s-2m oral test with set Θ1.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.734)
Θ1 0.8067 1 0.1744 4.626
Θ2 1.0835 1 0.2929 3.699
Θ3 0.7431 1 0.1169 6.354
Θ4 1.1978 1 0.1576 7.600
Table 4.21. Parameter estimation statistics for the 5h-22s-2m oral test with set Θ2.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.734)
Θ1 0.8856 1 0.2417 3.665
Θ2 1.0343 1 0.3032 3.411
Θ3 0.6769 1 0.2008 3.371
Θ4 1.9089 1 0.3921 4.868
4.7 3h-23s intravenous test
Similarly to the optimisation of the standard OGTT performed in the 5h-11s oral test,
this design aims at detecting the performance of an optimised standard IVGTT.
4.7.1 Experiment design
Considering the same duration and number of samples of the standard IVGTT, a
MBDoE approach is applied in order to identify the optimal sampling schedule. The
control variable for the optimisation is still the insulin infusion, which can be modified
over three time intervals (Table 4.22).
Since safety is a major concern, it is chosen to inject only two-thirds of the glucose
used in the standard IVGTT, i.e. 14 g. As a consequence, the glucose injection rate
reduces to 125 mg/dL/min. This is supposed to induce a considerable reduction in the
initial glucose peak, thus reducing the risk of an upper bound violation. However, since
the violation cannot be avoided completely, a small tolerance is allowed in order for
convergence to be reached, as shown in Table 4.23.
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Table 4.22. Controlled variable settings for the 3h-23s intravenous test design of experiment.
Insulin settings Value
Control type piecewise-constant
Intervals number 3
Interval lower bound [min] 10
Lower-Upper bounds [mU/min] 0-50
Table 4.23. End-point constraints for the 3h-23s intravenous test design of experiment.
Constrained variable Lower bound Upper bound
Lower bound violation [mg · min/dL] -0.01 0.01
Upper bound violation [mg · min/dL] -0.01 200
Gtot [mg/dL] 76.0 84.0
Γ [mg/(dL · min)] -0.1 0.1
The reduction in the glucose injection results in a sharp decrease of the initial spike
in the glucose concentration profile (Figure 4.8). Nevertheless, the upper bound viola-
tion is still present, even though negligible. The advantage of this protocol consists in
the good stabilisation of the final glucose concentration profile permitted by the short
stimulus induced on the subject.
(a) (b)
Figure 4.8. 3h-23s intravenous test: glucose profile from the MBDoE procedure and after parameter
identification with set Θ1 (a) and insulin administration profile (b).
As a result of the optimisation the time of the initial samples is postponed and
there is a higher concentration of samples in the final part of the test (Table 4.24).
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In addition, there is a good increase in the discrete information content derived with
respect to the standard IVGTT, which should result in an improved parameter esti-
mation capability. However, it can be noticed that the information achievable with
this optimised protocol remains below the one obtainable from the 5h-11s oral test.
This fact confirms what was previously observed in the preliminary analysis about the
higher information content of the standard OGTT over the standard IVGTT.
Table 4.24. Optimised design variables and discrete information content for the 3h-23s intravenous
test.
Variable Value
tsp [min] [28, 30, 32, 34, 61, 63, 65, 67, 69, 105, 108, 110, 112
114, 116, 118, 120, 172, 174, 176, 178, 180, 182]
U [mU/min] [49.57, 2.31, 18.23]
tU [min] [11.45, 36.83, 133.72]
Id 208.08
4.7.2 Parameter estimation
Figure 4.9 shows that the parametric mismatch still causes a significant gap between
the designed test on the healthy subject and the profile after identification with diabetic
sets. Nevertheless, due to the different type of stimulus induced by the glucose injection,
the violation of the upper bound remains quite limited regardless of the parametric set.
(a) (b)
Figure 4.9. Glucose profiles from the MBDoE procedure and after identification with set Θ1 (a) and
Θ2 (b) for the 3h-23s intravenous test.
The designed test exhibits an acceptable parameter estimation capability with set
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Θ1, although the second parameter is on the border line of acceptability (Table 4.25).
The limitations of this protocol clearly emerge when the parameter estimation with set
Θ2 is performed and statistically unsatisfactory estimates are obtained for the second
and third parameters (Table 4.26). Additionally, also the fourth parameter presents too
much a large confidence interval value, which makes the identification highly unreliable.
Table 4.25. Parameter estimation statistics for the 3h-23s intravenous test with set Θ1.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.729)
Θ1 0.7886 1 0.1149 6.864
Θ2 1.1464 1 0.6457 1.775
Θ3 0.8355 1 0.2726 3.065
Θ4 1.2037 1 0.1629 7.391
Table 4.26. Parameter estimation statistics for the 3h-23s intravenous test with set Θ2 (asterisks
denote t-values failing the t-test).
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.729)
Θ1 0.6557 1 0.1713 3.827
Θ2 3.6051 1 5.344 0.675*
Θ3 1.0708 1 1.7 0.630*
Θ4 1.8098 1 0.7203 2.513
4.8 3h-23s-2i intravenous test
The purpose of this design is to improve safety and identification performance of the
3h-23s intravenous test using two glucose injections.
4.8.1 Experiment design
The optimisation of the 23 samples is carried out adjusting three control variables: the
insulin infusion rate, the amount of glucose injected and the injection times.
Insulin infusion is manipulated over three intervals and narrower bounds, since less
glucose per injection is assumed by the patient. Manipulation of the amount of glucose
injected, along with no upper bound violation tolerated, allows to enclose the glucose
profile between the two bounds. The first glucose injection is forced to occur in the
first minute of the test, while the second one can move in the range from 40 to 100 min,
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as shown in Table 4.27.
As regards the other end-point constraints imposed on the design, they are the same
used in the 5h-22s-2m oral test (Table 4.18).
Table 4.27. Controlled variable settings for the 3h-23s-2i intravenous test design of experiment.
Insulin infusion Glucose injection Injection times
Control type piecewise-constant time-invariant time-invariant
Intervals number 3 1 1
Interval lower bound 10 min - -
Lower-Upper bounds 0-40 mU/min 50-120 mg/(dL·min) [1-1, 40-100] min
Figure 4.10 confirms that, similarly to the 3h-23s intravenous test, the type of stim-
ulus generated by an injection permits to stabilise the glucose profile and restore the
basal value in a simple way.
The design procedure yields two glucose injections, approximately of the same amount,
at a distance of an hour (Table 4.28).
At the same time, it can be noticed that the increment realised in the discrete informa-
tion content compared to the previously designed intravenous test is not so significant
as expected.
(a) (b)
Figure 4.10. 3h-23s-2i intravenous test: glucose profile from the MBDoE procedure (a) and insulin
administration profile (b).
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Table 4.28. Optimised design variables and discrete information content for the 3h-23s-2i intravenous
test.
Variable Value
tsp [min] [24, 26, 28, 30, 39, 59, 61, 74, 101, 103, 105, 107,
109, 111, 113, 115, 118, 172, 174, 176, 178, 180, 182]
Glucose injections [mg/(dL·min)] [90.52, 87.52]
tinjections [min] [0, 61]
U [mU/min] [27.81, 15.08, 16.06]
tU [min] [44.35, 69.06, 68.59]
Id 269.51
4.8.2 Parameter estimation
Figure 4.10 displays the good safety achieved with this test in the identification of dif-
ferent diabetic subjects, as it is proved by the negligible violations of the upper bound
observed. End-point glucose concentration is not very close to the basal value, but,
quite a flat end-profile is obtained.
Nevertheless, the poor identification performance of this new protocol can already be
perceived by looking at the fact that there is only slight improvement in the t-values
after identification with set Θ1 (Table 4.29) compared to the 3h-23s intravenous test.
In fact, from Table 4.30, it can be seen that this test fails in the estimation of the
second and third parameters with set Θ2.
(a) (b)
Figure 4.11. Glucose profiles from the MBDoE procedure and after identification with set Θ1 (a)
and Θ2 (b) for the 3h-23s-2i intravenous test.
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Table 4.29. Parameter estimation statistics for the 3h-23s-2i intravenous test with set Θ1.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.729)
Θ1 0.8080 1 0.1889 4.278
Θ2 1.5252 1 0.6223 2.451
Θ3 1.1467 1 0.4516 2.539
Θ4 1.1796 1 0.1390 8.486
Table 4.30. Parameter estimation statistics for the 3h-23s-2i intravenous test with set Θ2 (asterisks
denote t-values failing the t-test).
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.729)
Θ1 0.7275 1 0.2684 2.710
Θ2 1.3618 1 2.1570 0.631*
Θ3 0.7910 1 1.2280 0.644*
Θ4 1.3981 1 0.4021 3.477
4.9 Evaluation of the designed protocols
In this section, some considerations on the information content derived at different
conditions are pointed out and an overall assessment of the designed protocols is made.
4.9.1 Parametric bias on the information content
The glucose profiles previously examined for different parametric sets have shown that
the model parameters have a strong influence on the glucose response. To put it an-
other way, it means that each patient has his/her own parameters, which are initially
unknown and produce a different response to the same stimulus. The information
content derivable in a test is highly dependent on the parametric set of the subject
considered, hence it is not sensible to compare different tests based on distinct para-
metric sets.
Therefore, it is chosen to compare different tests only at the same parametric set. How-
ever, an issue could be raised regarding the fact that the choice of the specific set on
which to base the comparison could affect the corresponding result. With respect to
this, an empirical analysis has shown that for each test the following equality holds,
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regardless of the parametric set considered:
log
(
Id
Ic
)
= constant (4.3)
where Id and Ic represent the discrete and continuous information content realised with
the same parametric set, respectively. The use of the logarithm is due to the two/three
orders of magnitude difference between the discrete and continuous information.
In practical terms, Equation 4.3 means that the fraction of discrete information derived
over the continuous information potentially achievable is the same for a specific test for
every parametric set examined. This implies that if a test is found to be more informa-
tive than another for a certain parametric set then, also considering other parametric
sets, it will remain so. This can be visualised from the cumulative information content
graphs reported in Figure 4.12 for sets Θ1 and Θ2. The 5h-22s oral test is shown to
be the most informative for both sets and the same hierarchy is maintained also for
the other two tests.
(a) (b)
Figure 4.12. Comparison of the cumulative information content derivable from three designed pro-
tocols considering set Θ1 (a) and Θ2 (b).
4.9.2 Overall assessment
Beyond the capability to identify the model parameters in a statistically sound way,
the purpose of this work is to provide some criteria based on which to evaluate the
feasibility of the designed tests. In fact, the optimally devised protocol should be able
to identify an unknown subject while complying with the safety requirements needed
for its clinical implementation.
A novel approach is hereby introduced, which takes into account five distinct indices,
whose mathematical formulation has already been presented in § 2.8. These heuristic
indices allow to draw a comparison between different tests considering the factors that
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could impact the most on their applicability.
In light of the previous considerations, it is chosen to compare the tests on the basis
of set Θ2. Computation of the indices is performed considering safety and information
realised after the identification with that set. Therefore, only the tests that allow a
statistically satisfactory parameter estimation are taken into account, so as to avoid
deceiving results because of the great parametric mismatch. As a result of this, only
three designed protocols are displayed in Figure 4.13. The radar chart is a useful tool
Figure 4.13. Indices radar chart for the designed protocols that allow for a statistically satisfactory
parameter estimation with set Θ2.
for a quick evaluation of the most suitable clinical protocol based on the different in-
dices introduced. In fact, the larger the area of the polygon, the greater the suitability
of the designed test.
Firstly, the oral tests have been shown to outperform the intravenous ones for identi-
fication purposes, because they produce a more physiological type of stimulus on the
subject. As a matter of fact, only oral tests are represented in the radar chart.
Secondly, it can be easily noticed the rise in the information content that can be accom-
plished through an increase in the number of samples, i.e. a decrease in pi. Nevertheless,
this fact has a direct impact on the safety of the protocol: the 5h-22s oral test presents
the highest information index but, at the same time, its safety reaches a minimum.
The 5h-22s-2m represents a good compromise between high information content and
good safety, however, it has been shown to be difficult to restore basal glucose values
at the end of the test (Figure 4.7b) due to the second meal.
It is clear that none of these protocols completely meets the requirements needed for
a clinical application, even though valuable information has been derived. The major
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issue associated with these tests is represented by the rapid loss of their safety due
to the parametric mismatch. As a final consideration, some additional improvements
on safety are necessary, in order to guarantee a feasible implementation of the most
informative protocols.
Chapter 5
Robust design
This chapter deals with the design of a test that ensures the compliance of safety
requirements over a wide range of variability of the model parameters.
Firstly, the strategy adopted for the implementation of a robust design is presented.
Secondly, the effectiveness of such an approach in the design of a new protocol is shown,
in terms of safety enhancement and parameter estimation performance.
5.1 Introduction
In previous analyses, it has been shown that subject’s responses are highly dependent
on the parameter values. In other words, this means that a great variability in the
outputs is observed moving in the domain of uncertainty of the model parameters.
The main drawback associated with this fact consists in the large deviations of the glu-
cose profile from the design result, which can cause significant violations of the upper
bound.
In order to prevent the uncertainty of model parameters from leading to unsafe op-
erating conditions, robust design of experiment techniques may be implemented. A
successful application of this approach allows to design tests which are insensitive to
the starting value of the parameters. The method consists in the use of stochastic
simulations, which reproduce the physiological behaviour of a large group of diabetic
patients. The results are then applied to devise tests with stricter safety requirements,
so as to minimise the effect of parameter uncertainty when performed on unknown
subjects.
5.2 Variability assessment
The effect of the uncertainty of the model parameters on the glucose output is tested
on a population of 500 individuals affected by T1DM, adopting the 5 h-22 s oral test.
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The set of parameters of each of them is assigned randomly using a uniform distribution
within a certain range of variability. A uniform distribution is chosen because each
parameter is equally likely to be selected for the simulated patient. With respect to
the normalised set of parameters considered in the design stage for the healthy subject,
i.e. Θ0, the variability range assigned in the uniform distribution is the following:
[0.43− 0.73, 1.03− 1.20, 0.21− 0.40, 1.40− 1.60]
This choice has been made according to data reported in literature by Bergman [9] for
lean diabetic subjects.
Glucose profiles resulting from the 500 simulated patients are analysed by means of
some statistics, so as to assess their gap from the upper threshold. In particular, an
expected value approach is chosen, which considers the a priori uncertainty in the model
parameters by assuming that the parametric set to be used belongs to a population
of subjects, whose distribution is known, i.e. a uniform distribution over the range
specified above [42]. This method consists in selecting the maximum glucose value of
each profile and computing the mean and standard deviation over the entire population
taken into account.
Standard deviation (SD) is then used for designing robust tests, in which the upper
bound violation constraint is reformulated as:
dV1
dt
= max(0, Gtot(t)− UB + 2 · SD) (5.1)
A value of 19.53 for the standard deviation has been found but it has been chosen
to round it off to 20, so that the upper bound in the new design lowers from 170 to
130 mg/dL.
5.3 Robust oral test
The 5h-22s oral test has been detected the most informative among the several designs
presented in Chapter 4. Therefore, it is assumed as a reference for the development
of a clinical protocol which combines a satifactory identification capability with an
excellent safety.
5.3.1 Experiment design
An initial design is performed controlling both insulin infusion and the amount of
glucose of the meal, so as to be able to enforce the stricter constraint on the upper
threshold (Equation 5.1). Insulin infusion is controlled as for the 5h-22s oral test (Ta-
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ble 4.12), while the glucose meal can move in the range from 30 to 60 g. The end-point
constraints imposed on the design are similar to the 5h-22s-2m oral test (Table 4.18),
except for the glucose derivative constraint, which is relaxed in the range from -0.1 to
0.1. Relaxation of this constraint is required because otherwise the good excitation
pattern previously obtained is lost and, as a result, the parameter identification per-
formance is dramatically reduced.
A value close to 40 g is found for the meal from this preliminary design, so it is rounded
off to 40. Then, a new design is carried out fixing the meal at 40 g and controlling only
the insulin infusion with the same settings used before.
This designed protocol will be referred to as robust oral test. The results of this test,
i.e. sampling times and insulin infusion schedule, are reported in Table 5.1.
Table 5.1. Optimised design variables and discrete information content for the robust oral test.
Variable Value
tsp [min] [0, 37, 42, 47, 52, 57, 62, 107, 112, 117, 122, 180,
185, 190, 195, 200, 275, 280, 285, 290, 295, 300]
U [mU/min] [100, 0, 18.62]
tU [min] [35.78, 98.39, 165.83]
Id 413.29
The high value found for the discrete information content, which is slightly lower
than the 5h-22s oral test, indicates that good parameter estimates can possibly be
achieved with this new protocol.
In addition to good identification performance, the objective of the robust design is
primarily that of guaranteeing safety conditions to the unknown patient. At this pur-
pose, the robust oral test can be compared to an identical design obtained at the same
conditions but using the original upper bound constraint, i.e. 170 mg/dL. Initially,
another preliminary design is performed adjusting both insulin infusion and glucose
administration, which now varies in the range from 30 to 70 g. A value of 62.23 g is
obtained, thus it is rounded off to 62 g.
Fixing the glucose meal at this value, a new design is carried out in which only the
insulin infusion is controlled as before. The results of the new protocol, which will be
referred to as non robust oral test, are presented in Table 5.2.
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Table 5.2. Optimised design variables and discrete information content for the non robust oral test.
Variable Value
tsp [min] [0, 44, 49, 54, 59, 98, 103, 108, 113, 124, 131, 171,
181, 191, 196, 201, 222, 251, 285, 290, 295, 300]
U [mU/min] [99.30, 0, 18.65]
tU [min] [48.93, 93.26, 157.82]
Id 490.03
It can be noticed that the non robust oral test is even more informative than the
5h-22s oral test (Table 4.14), because it induces a higher stimulus in the subject push-
ing the glucose profile towards both bounds (Figure 5.1a). Similarly, the robust oral
test, thanks to the reduced glucose meal, presents a similar behaviour but allows to
maintain the glucose profile below the new upper bound imposed by the robust design.
As regards insulin infusion, Figure 5.1b shows that the two profiles are approximately
equivalent. A slightly longer insulin infusion is required in the non robust oral test,
since a greater glucose meal is applied.
(a) (b)
Figure 5.1. Comparison between robust and non robust oral tests: glucose profile from the MBDoE
procedure (a) and insulin administration profile (b).
5.3.2 Parameter estimation
The effectiveness of the robust design can be shown performing a parameter estimation
task with set Θ2. Figure 5.2 shows the glucose profiles after identification with that
set for the robust and the non robust oral tests. Experimental measurements are not
displayed in the graph for the sake of clarity. It can be observed that the robust oral
test succeeds in maintaining the glucose profile within the upper bound, even though
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set Θ2 does not belong to the population of subjects simulated in the robust design,
for the reasons pointed out in § 4.1.1.
Figure 5.2. Glucose profiles of the robust and non robust oral tests after identification with set Θ2.
The robust protocol devised does not guarantee that no violation of the upper
threshold is obtained for any choice of the parametric set. Nevertheless, since an ex-
pected value approach has been used, it ensures that, at least in a neighbourohood of
the variability range taken into account in the robust design, the violation is limited.
In terms of parameter estimation performance, both tests permit to identify the model
parameters with set Θ2 in a statistically sound way. A light improvement in the es-
timates is observed in the non robust oral test, due to the higher information content
realised. However, since the focus is now on safety, only the robust oral test estimates
are reported in Table 5.3.
Table 5.3. Parameter estimation statistics for the robust oral test with set Θ2.
Parameter Final value Initial guess Confidence interval 95% 95% t-value (Ref. 1.734)
Θ1 0.6999 1 0.1347 5.196
Θ2 1.3043 1 0.1519 8.589
Θ3 0.6193 1 0.0961 6.447
Θ4 1.5739 1 0.2424 6.493
A comparison between these estimates and those achieved with the 5h-22s oral
test (Table 4.16) shows that the effect of the loss of information content due to safety
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enforcement is not so evident. In fact, the t-values prove that, for the second and third
parameter, better estimates are achieved using the robust oral test.
5.4 Final considerations
The non robust oral test seems to grant an enhancement of the information content
compared to the 5h-22s oral test. However, since the primary concern of the robust
design is to ensure safety conditions to the subject, the non robust oral test is excluded
from further analyses.
Figure 5.3 presents a comparison based on the 5 heuristic indices between the 5h-22s
oral test and the robust oral test.
Figure 5.3. Indices radar chart: comparison between the 5h-22s oral test and the robust oral test
after parameter estimation with set Θ2.
The first one has been shown to be the most informative among all the designed
protocols, while the latter exhibits the highest safety. Taking merely the areas of the
two polygons into account, the robust oral test clearly outperforms the 5h-22s oral test
in an overall assessment. As a consideration related to this fact, it is important to
highlight the effectiveness of the implementation of a robust approach in the design of
clinical tests.
Additionally, it should be clear that the more information is desired, the less safety
is achieved. This fact has clearly emerged from the previous comparison between the
robust and the non robust oral tests. Broadly speaking, the implementation of stricter
safety requirements in the design phase, due to the robust approach, causes a reduction
of the degrees of freedom available. As a result, a lesser stimulus can be induced on the
patient, at least considering the same duration for the test, thus a lower information
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content can be accomplished.
As a final consideration, the research of an optimal clinical protocol for parameter
identification seems to be more the result of a compromise on the highest information
achievable at the maximum safety, rather than a simultaneous maximisation of both
of them.
Beyond safety conditions over the entire duration of the test, the optimal protocol is
also required to restore basal glucose values at the end of it. Nevertheless, this re-
quirement is not simple to be satisfied, since its direct implementation in the MBDoE
would result in a further decrease of the degrees of freedom available, hence a much
more complex design. Therefore, a different procedure has been followed, in order to
assure the compliance of this condition, based on the results obtained at the end of the
test.
Figure 5.4. Glucose profiles of the robust oral test with sets Θ1 and Θ2 over a 350 min duration
(test ends at 300 min).
Figure 5.4 shows the behaviour of glucose concentrations with sets Θ1 and Θ2 once
the robust oral test terminates, i.e. at 300 min. As previously observed in Figure 5.2,
glucose profile is not flat at the end of the test, due to the parametric mismatch. How-
ever, suspending insulin infusion at 300 min, a stabilisation of glucose concentration is
achieved after a while, followed by a rapid increase due to the lack of insulin adminis-
tration.
This fact is confirmed by looking at the values of the glucose derivative reported in
Table 5.4: after 10 min in both cases the derivatives fall in the range imposed in the
design, i.e. -0.1 < Γ < 0.1.
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Table 5.4. Glucose derivative and glucose concentration values at the end of the robust oral test and
10 min after with sets Θ1 and Θ2.
Parametric set Γ @ 300 min Γ @ 310 min Gtot @ 300 min Gtot @ 310 min
[mg/(dL · min)] [mg/(dL · min)] [mg/dL] [mg/dL]
Θ1 -0.13 0.06 90.97 90.38
Θ2 -0.20 -0.03 105.60 104.30
As for the final glucose values achieved, it should be considered that they are not
too far from the basal value, i.e. 80 mg/dL, so they can be easily restored under
the supervision of the medical staff or, alternatively, with the patient’s knowledge of
himself/herself.
Conclusions
The purpose of this thesis was to devise a feasible clinical protocol for the identification
of physiological models of T1DM. The Lynch-Bequette model has been assumed as the
reference model in this analysis, which has been entirely conducted by means of the
software gPROMSr.
The investigation has departed from the tests currently used in clinical facilities for dia-
betes diagnosis and research purposes: the standard OGTT and the standard IVGTT.
A preliminary analysis has provided some valuable knowledge on them, such as the
more physiological stimulus induced by an oral test and the higher information content
derivable from it.
The chief part of the work has been the design of new clinical tests applying a MBDoE
approach. Firstly, the poor performance of the two standard tests has been demon-
strated, motivating the search of reliable alternatives. Secondly, five protocols have
been enquired, primarily in terms of parameter estimation capability, using two dis-
tinct parametric sets representing different degrees of diabetes severity.
The design procedure applied to the standard tests has shown considerable improve-
ments in both cases. However, at the same time, it has highlighted the superiority of
an oral test over an intravenous one for parameter estimation purposes. In fact, the
5h-11s oral test succeeds in this task, while the 3h-23s intravenous test fails, due to
its poor stimulus. This hurdle cannot be overcome even using two glucose injections
(3h-23s-2i intravenous test), although excellent safety standards are exhibited during
the test.
Focusing on the oral tests, the 5h-22s oral test has shown the most satisfactory param-
eter estimation performance among the designed protocols, along with a simple insulin
infusion profile. The main issue related to this protocol is its unsatisfactory safety,
especially in the identification of patients with severe parametric deviations from the
healthy subject. As a countermeasure to this problem, a different protocol has been
examined based on two glucose meals of reduced quantity. The resulting 5h-22s-2m
oral test has only partially met the safety requirements desired for a clinical implemen-
tation and, at the same time, it has shown some difficulties in restoring the glucose
basal value at the end of it.
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It has been noticed that there is a strong dependence of the model outputs on the
parameters, which causes significant deviations from the designed profiles, putting
sometimes the subject at risk. In turn, there is also a bias of the information con-
tent due to the parametric set, which needs to be considered when comparing different
tests. In light of the constant ratio between the discrete and continuous information
content for the same test, regardless of the parametric set, an assessment of the most
informative protocol is allowed.
The evaluation of the overall feasibility requirements of the tests has been based on
five indices. The invasivity index cannot be improved with the kind of tests taken into
account, duration can hardly be reduced for identification purposes, while the number
of samples has been maintained at a sensible value, since it is directly linked to the
information derivable. However, the MBDoE procedure has shown its effectiveness in
maximising the information content while enforcing constraints on the safety.
The lack of a reliable protocol has triggered further investigation, which has entailed
the application of a robust design approach. Starting from the most informative and
least safe protocol (i.e. 5h-22s oral test), this method has allowed to design a highly
reliable clinical protocol (robust oral test). This test is endowed with high robustness,
that is its safety is quite insensitive to the parameter values, which is a major concern
when an unknown subject is to be identified. In addition, it assures a statistically
satisfactory parameter estimation, even though some information content is inevitably
lost. As a final consideration, this protocol seems suitable because it has a simple
insulin infusion profile and glucose values close to basal are restored at the end of it.
Future developments may involve the application of a multi-objective design strategy,
where information content and safety are both optimised at the same time. Addition-
ally, it could be interesting to take into consideration oral insulin administrations, so
as to minimise the invasivity on the subject.
Notations
Symbols
A glucose meal [g]
BW body weight [kg]
D glucose intake velocity [mg/dL/min]
G glucose concentration [mg/dL]
Gb basal glucose concentration [mg/dL]
Gsc glucose concentration in the subcutaneous layer [mg/dL]
Gtot total glucose concentration [mg/dL]
I difference between blood and basal insulin [mU/L]
Ib basal insulin concentration [mU/L]
Ic continuous information content [-]
Id discrete information content [-]
Id,max maximum discrete information content among all the
tests [-]
Ki confidence interval [-]
LB lower glucose bound [mg/dL]
Nθ number of model parameters [-]
nmax maximum number of samples allowed in a test [-]
nsp number of blood samples taken in a test [-]
nsw number of switching levels of a control variable [-]
Nu number of manipulated inputs [-]
Nw number of time invariant controls [-]
Nx number of state variables [-]
Ny number of measured variables [-]
Nθ number of model parameters [-]
qi i -th element of the dynamic sensitivity matrix [-]
Rut glucose usage velocity in tissues [mg/dL/min]
sij ij -th element of the inverse matrix of Σ [-]
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SG glucose effectiveness [min
−1]
SI insulin sensitivity [mU·min/L]
t time [min]
t¯ t-value [-]
t0 initial time [min]
tmax maximum test duration [min]
tmax,G time-to-maximum of glucose uptake [min]
tsp glucose sampling time [min]
ttest test duration [min]
U exogenous insulin infusion rate [mU/min]
Uv intravenous glucose injection rate [mg/dL/min]
UB upper glucose bound [mg/dL]
V1 glucose lower bound violation [mg·min/dL]
V2 glucose upper bound violation [mg·min/dL]
Vg glucose distribution volume [dL/kg]
Vi insulin distribution volume [L]
X insulin concentration in the remote compartment [mU/L]
Greek letters
α invasivity index [-]
αglucose glucose invasivity index [-]
αinsulin insulin invasivity index [-]
α% confidence region [-]
β safety index [-]
β
′
total bound violation of a test [mg·min/dL]
βmax maximum bound violation observed in the OGTT [mg·min/dL]
γ information content index [-]
Γ time derivative of glucose concentration at the end
of a test [mg/dL/min]
γi heteroschedastic factor [-]
θi i -th model parameter [-]
θ
′
i i -th perturbated parameter [-]
λk k -th eigenvalue [-]
νii element on the diagonal of the variance-covariance
matrix [-]
pi sample index [-]
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σi standard deviation of the i -th response yˆi [-]
τ test duration index [-]
ΦLS objective function for LS parameter estimation [-]
ΦML objective function for ML parameter estimation [-]
ΦWLS objective function for WLS parameter estimation [-]
χ2 chi-square [-]
Vectors and matrices
χ2ref reference chi-square [-]
Ψ Vθ measurement function [-]
ωi standard deviation of the i -th measured response [-]
Hθ Fisher information matrix [NθxNθ]
H0θ preliminary Fisher information matrix [NθxNθ]
Q sensitivity matrix [nspxNθ]
tsp vector of sampling times [nsp]
tsw vector of switching times [nsw+1]
u vector of time-dependent control variables [Nu]
Vθ variance-covariance matrix of model parameters [NθxNθ]
w vector of time-invariant control variables [Nw]
x vector of state variables [Nx]
y measurements vector [Ny]
yˆ vector of estimated responses [Ny]
zsw vector of switching levels [nsw]
yˆ vector of estimated values of model parameters [Nθ]
θ0 vector of initial model parameters [Nθ]
Θ0 vector of normalised initial model parameters [Nθ]
Θ1 first vector of normalised model parameters for the subject [Nθ]
Θ2 second vector of normalised model parameters for the subject [Nθ]
Σi measurement errors variance-covariance matrix in the i -th
experiment [NyxNy]
Σθ prior variance-covariance matrix of model parameters [NθxNθ]
ϕ design vector [nϕ]
ϕopt optimal design vector [nϕ]
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Acronyms
CGMS continuous glucose monitoring system
GDM gestational diabetes mellitus
IVGTT intravenous glucose tolerance test
LB Lynch and Bequette model
LS least squares
MBDoE model-based design of experiments
ML maximum likelyhood
MPC model predictive control
OGTT oral glucose tolerance test
SWR sum of weighted residuals
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
WAP wearable artificial pancreas
WHO World Health Organization
WLS weighted least squares
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